Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Системная красная волчанка

Список литературы

  1. Petty RE, Laxer RM, Lindsley CB, et al. Textbook of pediatric rheumatology. 8th ed. Philadelphia: Elsevier, Inc 2020.
  2. Баранов АА, Алексеева ЕИ, editors. Ревматические болезни у детей. Москва: : ПедиатрЪ 2016.
  3. Harry O, Yasin S, Brunner H. Childhood-Onset Systemic Lupus Erythematosus: A Review and Update. J Pediatr. 2018;196:22-30.e2. doi: 10.1016/j.jpeds.2018.01.045
  4. Zucchi D, Elefante E, Calabresi E, et al. One year in review 2019: systemic lupus erythematosus. Clin Exp Rheumatol. 2019;37:715–22.
  5. Rullo OJ, Tsao BP. Recent insights into the genetic basis of systemic lupus erythematosus. Ann Rheum Dis. 2013;72:ii56–61. doi: 10.1136/annrheumdis-2012-202351
  6. Trindade VC, Carneiro-Sampaio M, Bonfa E, et al. An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus. Pediatr Drugs. 2021;23:331–47. doi: 10.1007/s40272-021-00457-z
  7. Chen L, Morris DL, Vyse TJ. Genetic advances in systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2017;29:423–33. doi: 10.1097/BOR.0000000000000411
  8. Demirkaya E, Sahin S, Romano M, et al. New Horizons in the Genetic Etiology of Systemic Lupus Erythematosus and Lupus-Like Disease: Monogenic Lupus and Beyond. J Clin Med. 2020;9:712. doi: 10.3390/jcm9030712
  9. Liphaus BL, Caramalho I, Rangel-Santos A, et al. LRBA deficiency: a new genetic cause of monogenic lupus. Ann Rheum Dis. 2020;79:427–8. doi: 10.1136/annrheumdis-2019-216410
  10. Costa-Reis P, Sullivan KE. Monogenic lupus: it’s all new! Curr Opin Immunol. 2017;49:87–95. doi: 10.1016/j.coi.2017.10.008
  11. Hughes GC, Choubey D. Modulation of autoimmune rheumatic diseases by oestrogen and progesterone. Nat Rev Rheumatol. 2014;10:740–51. doi: 10.1038/nrrheum.2014.144
  12. Krasselt M, Baerwald C. Sex, Symptom Severity, and Quality of Life in Rheumatology. Clin Rev Allergy Immunol. 2019;56:346–61. doi: 10.1007/s12016-017-8631-6
  13. Lehmann P, Hölzle E, Kind P, et al. Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Dermatol. 1990;22:181–7. doi: 10.1016/0190-9622(90)70020-I
  14. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med. 1994;179:1317–30. doi: 10.1084/jem.179.4.1317
  15. Gergianaki I, Bortoluzzi A, Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2018;32:188–205. doi: 10.1016/j.berh.2018.09.004
  16. Jin O, Kavikondala S, Sun L, et al. Systemic lupus erythematosus patients have increased number of circulating plasmacytoid dendritic cells, but decreased myeloid dendritic cells with deficient CD83 expression. Lupus. 2008;17:654–62. doi: 10.1177/0961203308089410
  17. Saferding V, Blüml S. Innate immunity as the trigger of systemic autoimmune diseases. J Autoimmun. 2020;110:102382. doi: 10.1016/j.jaut.2019.102382
  18. Machida H, Ito S, Hirose T, et al. Expression of Toll-like receptor 9 in renal podocytes in childhood-onset active and inactive lupus nephritis. Nephrol Dial Transplant. 2010;25:2430–537. doi: 10.1093/ndt/gfq058
  19. Postal M, Sinicato NA, Peliçari KO, et al. Clinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus. Clinics. 2012;67:157–62. doi: 10.6061/clinics/2012(02)11
  20. Lo MS. Insights Gained From the Study of Pediatric Systemic Lupus Erythematosus. Front Immunol. 2018;9:1278. doi: 10.3389/fimmu.2018.01278
  21. Macedo ACL, Isaac L. Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway. Front Immunol. 2016;7. doi: 10.3389/fimmu.2016.00055
  22. Mak A, Kow NY. The Pathology of T Cells in Systemic Lupus Erythematosus. J Immunol Res. 2014;2014:1–8. doi: 10.1155/2014/419029
  23. Tsokos GC, Lo MS, Reis PC, et al. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12:716–30. doi: 10.1038/nrrheum.2016.186
  24. Singla S, Wenderfer SE, Muscal E, et al. Changes in Frequency and Activation Status of Major CD4+ T-Cell Subsets after Initiation of Immunosuppressive Therapy in a Patient with New Diagnosis Childhood-Onset Systemic Lupus Erythematosus. Front Pediatr. 2017;5:104. doi: 10.3389/fped.2017.00104
  25. Smith EMD, Lythgoe H, Midgley A, et al. Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. Clin Immunol. 2019;209:108274. doi: 10.1016/j.clim.2019.108274
  26. Hong SD, Reiff A, Yang H, et al. B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients. Arthritis Rheum. 2009;60:3400–9. doi: 10.1002/art.24902
  27. Steinberg A. Insights into the basis of systemic lupus. J Autoimmun. 1995;8:771–85. doi: 10.1016/S0896-8411(95)80017-4
  28. Via CS, Handwerger BS. B-cell and T-cell function in systemic lupus erythematosus: Curr Opin Rheumatol. 1993;5:570–4. doi: 10.1097/00002281-199305050-00004
  29. Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol. 2010;6:538–46. doi: 10.1038/nrrheum.2010.121
  30. Hiraki LT, Benseler SM, Tyrrell PN, et al. Clinical and Laboratory Characteristics and Long-Term Outcome of Pediatric Systemic Lupus Erythematosus: A Longitudinal Study. J Pediatr. 2008;152:550–6. doi: 10.1016/j.jpeds.2007.09.019
  31. Pluchinotta FR, Schiavo B, Vittadello F, et al. Distinctive clinical features of pediatric systemic lupus erythematosus in three different age classes. Lupus. 2007;16:550–5. doi: 10.1177/0961203307080636
  32. Fortuna G, Brennan MT. Systemic Lupus Erythematosus. Dent Clin North Am. 2013;57:631–55. doi: 10.1016/j.cden.2013.06.003
  33. Насонова ВА. Системная красная волчанка. Москва: 1972.
  34. Brunner HI, Feldman BM, Bombardier C, et al. Sensitivity of the systemic lupus erythematosus disease activity index, British Isles lupus assessment group index, and systemic lupus activity measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 1999;42:1354–60. doi: 10.1002/1529-0131(199907)42:7<1354::AID-ANR8>3.0.CO;2-4
  35. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736–45. doi: 10.1136/annrheumdis-2019-215089
  36. Garcia-Diaz J, Escudero-Salamanca M, Alvarez-Santana R, et al. Catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus: a case-based review. Future Cardiol. 2021;17:985–90. doi: 10.2217/fca-2020-0145
  37. Papachristos DA, Oon S, Hanly JG, et al. Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review. Semin Arthritis Rheum. 2021;51:49–71. doi: 10.1016/j.semarthrit.2020.12.004
  38. Gattorno M, Buoncompagni A, Molinari AC, et al. Antiphospholipid antibodies in paediatric systemic lupus erythematosus, juvenile chronic arthritis and overlap syndromes: sle patients with both lupus anticoagulant and high-titre anticardiolipin antibodies are at risk for clinical manifestations related to the antiphospholipid syndrome. Rheumatology. 1995;34:873–81. doi: 10.1093/rheumatology/34.9.873
  39. Fanouriakis A, Tziolos N, Bertsias G, et al. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80:14–25. doi: 10.1136/annrheumdis-2020-218272
  40. Groot N, De Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis. 2017;76:1788–96. doi: 10.1136/annrheumdis-2016-210960
  41. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771–82. doi: 10.1136/annrheumdis-2012-201940
  42. Chanprapaph K, Tubtieng I, Pratumchat N, et al. Cutaneous, systemic features and laboratory characteristics of late- versus adult-onset systemic lupus erythematosus in 1006 Thai patients. Lupus. 2021;30:785–94. doi: 10.1177/0961203321991920
  43. Chottawornsak N, Rodsaward P, Suwannachote S, et al. Skin signs in juvenile- and adult-onset systemic lupus erythematosus: clues to different systemic involvement. Lupus. 2018;27:2069–75. doi: 10.1177/0961203318805851
  44. Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78:1296–304. doi: 10.1136/annrheumdis-2019-215213
  45. Pinheiro SVB, Dias RF, Fabiano RCG, et al. Pediatric lupus nephritis. Braz J Nephrol. 2019;41:252–65. doi: 10.1590/2175-8239-jbn-2018-0097
  46. Satish S, Deka P, Shetty MS. A clinico-pathological study of lupus nephritis based on the International Society of Nephrology-Renal Pathology Society 2003 classification system. J Lab Physicians. 2017;9:149–55. doi: 10.4103/JLP.JLP_44_16
  47. Magro-Checa C, Zirkzee EJ, Huizinga TW, et al. Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. Drugs. 2016;76:459–83. doi: 10.1007/s40265-015-0534-3
  48. Division of Pediatric Rheumatology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA, Madison JA, Zuo Y, et al. Pediatric antiphospholipid syndrome. Eur J Rheumatol. 2020;7:3–12. doi: 10.5152/eurjrheum.2019.19160
  49. Weening JJ, D’agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521–30. doi: 10.1111/j.1523-1755.2004.00443.x
  50. Alexeeva EI, Dvoryakovskaya TM, Nikishina IP, et al. Systemic lupus erythematosus: clinical recommendations. Part 1. Curr Pediatr. 2018;17:19–37. doi: 10.15690/vsp.v17i1.1853
  51. Ceccarelli F, Perricone C, Cipriano E, et al. Joint involvement in systemic lupus erythematosus: From pathogenesis to clinical assessment. Semin Arthritis Rheum. 2017;47:53–64. doi: 10.1016/j.semarthrit.2017.03.022
  52. Federici S, Gattorno M. A practical approach to the diagnosis of autoinflammatory diseases in childhood. Best Pract Res Clin Rheumatol. 2014;28:263–76. doi: 10.1016/j.berh.2014.05.005
  53. Bueno GCL, Koerich ATDS, Burg LB, et al. Visceral leishmaniasis mimicking systemic lupus erythematosus. Rev Soc Bras Med Trop. 2019;52:e20180208. doi: 10.1590/0037-8682-0208-2018
  54. Chasset F, Richez C, Martin T, et al. Rare diseases that mimic Systemic Lupus Erythematosus (Lupus mimickers). Joint Bone Spine. 2019;86:165–71. doi: 10.1016/j.jbspin.2018.10.007
  55. Alawieh R, Satoskar A, Obole E, et al. Infection-related glomerulonephritis mimicking lupus nephritis. Clin Nephrol. 2020;94:212–4. doi: 10.5414/CN110202
  56. Li JC ‐H., Fong W, Wijaya L, et al. Disseminated tuberculosis masquerading as a presentation of systemic lupus erythematosus. Int J Rheum Dis. 2018;21:352–5. doi: 10.1111/1756-185X.13195
  57. Kiriakidou M, Ching CL. Systemic Lupus Erythematosus. Ann Intern Med. 2020;172:ITC81–96. doi: 10.7326/AITC202006020
  58. Hernandez J, Polo R, Alvarez J, et al. [A “lupus-like” syndrome as the form of presentation of pulmonary adenocarcinoma]. An Med Interna Madr Spain 1984. 2000;17:558–9.
  59. Calixto O-J, Franco J-S, Anaya J-M. Lupus mimickers. Autoimmun Rev. 2014;13:865–72. doi: 10.1016/j.autrev.2014.05.002
  60. Soon GS, Laxer RM. Approach to recurrent fever in childhood. Can Fam Physician Med Fam Can. 2017;63:756–62.
  61. Littlejohn E, Marder W, Lewis E, et al. The ratio of erythrocyte sedimentation rate to C-reactive protein is useful in distinguishing infection from flare in systemic lupus erythematosus patients presenting with fever. Lupus. 2018;27:1123–9. doi: 10.1177/0961203318763732
  62. Pande I, Sekharan NG, Kailash S, et al. Analysis of Clinical and Laboratory Profile in Indian Childhood Systemic Lupus Erythematosus and its Comparison with SLE in Adults. Lupus. 1993;2:83–7. doi: 10.1177/096120339300200204
  63. Kisaoglu H, Baba O, Kalyoncu M. Hematologic manifestations of juvenile systemic lupus erythematosus: An emphasis on anemia. Lupus. 2022;31:730–6. doi: 10.1177/09612033221093508
  64. Mohd Shukri ND, Wan Mohamad WM, Wan Ab Rahman WS. Childhood-Onset Systemic Lupus Erythematosus Presenting With Concomitant Gastrointestinal Manifestation and Antiphospholipid Syndrome. Cureus. Published Online First: 21 November 2023. doi: 10.7759/cureus.49205
  65. Li J, Jiang J-J, Wang C-Y, et al. Clinical features and prognosis of patients with thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a review of 25 cases. Ital J Pediatr. 2019;45:55. doi: 10.1186/s13052-019-0641-y
  66. Van Den Akker M, Silverman E, Abdelhaleem M, et al. Aplastic anemia associated with systemic lupus erythematosus in children – case report and review of the literature. Clin Case Rep. 2014;2:319–22. doi: 10.1002/ccr3.123
  67. Stabile A, Bertoni B, Ansuini V, et al. The clinical spectrum and treatment options of macrophage activation syndrome in the pediatric age. Eur Rev Med Pharmacol Sci. 2006;10:53–9.
  68. Gottlieb BS, Ilowite NT. Systemic Lupus Erythematosus in Children and Adolescents. Pediatr Rev. 2006;27:323–30. doi: 10.1542/pir.27.9.323
  69. Breda, L., Nozzi, M., De Sanctis, S., & Chiarelli, F. (2010). Laboratory Tests in the Diagnosis and Follow-Up of Pediatric Rheumatic Diseases: An Update. Seminars in Arthritis and Rheumatism, 40(1), 53–72. doi:10.1016/j.semarthrit.2008.12.
  70. Mauro A, Giani T, Di Mari C, et al. Gastrointestinal Involvement in Children with Systemic Lupus Erythematosus. Children. 2023;10:309. doi: 10.3390/children10020309
  71. Ardoin S, Sandborg C, Schanberg L. Review: Management of dyslipidemia in children and adolescents with systemic lupus erythematosus. Lupus. 2007;16:618–26. doi: 10.1177/0961203307079566
  72. Wincup C, Sawford N, Rahman A. Pathological mechanisms of abnormal iron metabolism and mitochondrial dysfunction in systemic lupus erythematosus. Expert Rev Clin Immunol. 2021;17:957–67. doi: 10.1080/1744666X.2021.1953981
  73. Aydin H, Bucak İ, Taştan S. Serebral Palsili Çocuklarda B12 Vitamini Düzeyleri Neden Yüksek ? Hippocrates Med J. Published Online First: 9 May 2023. doi: 10.58961/hmj.1230922
  74. Lorber M, Gershwin ME, Shoenfeld Y. The coexistence of systemic lupus erythematosus with other autoimmune diseases: The kaleidoscope of autoimmunity. Semin Arthritis Rheum. 1994;24:105–13. doi: 10.1016/S0049-0172(05)80004-6
  75. Malleson P, Tekano J. Diagnosis and management of systemic lupus erythematosus in children. Paediatr Child Health. 2008;18:61–9. doi: 10.1016/j.paed.2007.10.009
  76. Králíčková P, Malá E, Vokurková D, Souček O, Krčmová I, Hrnčíř Z. Sekundární humorální imunodeficience u nemocných se systémovým lupus erythematodes [Secondary humoral immunodeficiency in patiens with systemic lupus erythematosus]. Vnitr Lek. 2015 Sep;61(9):778-84. Czech. PMID: 26465276.
  77. Almaghlouth I, Johnson SR, Pullenayegum E, Gladman D, Urowitz M. Immunoglobulin levels in systemic lupus erythematosus: A narrative review. Lupus. 2021 May;30(6):867-875. doi: 10.1177/09612033211004714. Epub 2021 Mar 28. PMID: 33779380.
  78. Yaniv G, Twig G, Shor DB-A, et al. A volcanic explosion of autoantibodies in systemic lupus erythematosus: A diversity of 180 different antibodies found in SLE patients. Autoimmun Rev. 2015;14:75–9. doi: 10.1016/j.autrev.2014.10.003
  79. Shaoxian H, Deding T, Peigen H. Immunophenotyping of lymphocyte T and B in the peripheral blood of systemic lupus erythematosus. Curr Med Sci. 2001;21:108–9. doi: 10.1007/BF02888069
  80. Perry DJ, Titov AA, Sobel ES, et al. Immunophenotyping reveals distinct subgroups of lupus patients based on their activated T cell subsets. Clin Immunol. 2020;221:108602. doi: 10.1016/j.clim.2020.108602
  81. Gong H, Shi C, Zhou Z, et al. Evaluating hypercoagulability in new‐onset systemic lupus erythematosus patients using thromboelastography. J Clin Lab Anal. 2020;34:e23157. doi: 10.1002/jcla.23157
  82. Afeltra A, Vadacca M, Conti L, et al. Thrombosis in systemic lupus erythematosus: Congenital and acquired risk factors. Arthritis Rheum. 2005;53:452–9. doi: 10.1002/art.21172
  83. Manco-Johnson MJ. How I treat venous thrombosis in children. Blood. 2006;107:21–9. doi: 10.1182/blood-2004-11-4211
  84. Tolbert J, Carpenter SL. Common Acquired Causes of Thrombosis in Children. Curr Probl Pediatr Adolesc Health Care. 2013;43:169–77. doi: 10.1016/j.cppeds.2013.05.005
  85. Komvilaisak P, Wisanuyotin S, Jettrisuparb A, et al. Lupus Anticoagulant-hypoprothrombinemia Syndrome (LAC-HPS) in Children With Systemic Lupus Erythematosus: Report of 3 Cases. J Pediatr Hematol Oncol. 2017;39:e521–4. doi: 10.1097/MPH.0000000000000891
  86. Li Z, Xiao J, Song H, et al. Evaluation of coagulation disorders by thromboelastography in children with systemic lupus erythematosus. Lupus. 2019;28:181–8. doi: 10.1177/0961203318819137
  87. Ikejiaku UP, Ezerioha OP, Nwaoha CA, et al. Autoimmune Haemolytic Anaemia as Initial and Only Presentation of Systemic Lupus Erythematosus: A Case Report. Int J Trop Dis Health. 2023;44:21–8. doi: 10.9734/ijtdh/2023/v44i231501
  88. Lu Y, Huang X-M. Autoimmune hemolytic anemia as an initial presentation in children with systemic lupus erythematosus: two case reports. J Int Med Res. 2022;50:030006052211153. doi: 10.1177/03000605221115390
  89. Abdel-Salam A, Bassiouni ST, Goher AM, et al. Autoimmune Hemolytic Anemia in the Pediatric Age Group: The Egyptian Experience. Ann Hematol. 2023;102:1687–94. doi: 10.1007/s00277-023-05230-5
  90. Ronchezel MV, Len CA, Spinola E Castro A, et al. Thyroid Function and Serum Prolactin Levels in Patients with Juvenile Systemic Lupus Erythematosus. J Pediatr Endocrinol Metab. 2001;14. doi: 10.1515/JPEM.2001.14.2.165
  91. Oni L, Wright RD, Marks S, et al. Kidney outcomes for children with lupus nephritis. Pediatr Nephrol. 2021;36:1377–85. doi: 10.1007/s00467-020-04686-1
  92. Limper M, de Kruif MD, Duits AJ, et al. The diagnostic role of Procalcitonin and other biomarkers in discriminating infectious from non-infectious fever. J Infect. 2010;60:409–16. doi: 10.1016/j.jinf.2010.03.016
  93. Ospina FE, Echeverri A, Zambrano D, et al. Distinguishing infections vs flares in patients with systemic lupus erythematosus: Table 1. Rheumatology. 2016;kew340. doi: 10.1093/rheumatology/kew340
  94. Janarthanan M, Antony T, Mohan R, et al. Disseminated tuberculosis with macrophage activation syndrome in a child with lupus nephritis. Sudan J Paediatr. 2021;190–4. doi: 10.24911/SJP.106-1614333951
  95. Aksenova VA, Klevno NI, Kazakov AV, et al. Preventive Tuberculosis Services Reduces the Risk of Local Forms of Tuberculosis Development in Children on Immunosuppressive Therapy: Retrospective Cohort Study. Curr Pediatr. 2020;19:346–51. doi: 10.15690/vsp.v19i5.2210
  96. Maduemem KE, Adedokun CO, Vatca A. Combined Diagnosis of Systemic Lupus Erythematosus and Tuberculosis in an Irish Adolescent Female. Case Rep Pediatr. 2018;2018:1–4. doi: 10.1155/2018/2031219
  97. Calzada-Hernández J, Anton J, Martín De Carpi J, et al. Dual latent tuberculosis screening with tuberculin skin tests and QuantiFERON-TB assays before TNF-α inhibitor initiation in children in Spain. Eur J Pediatr. 2022;182:307–17. doi: 10.1007/s00431-022-04640-3
  98. Бармина НА, Барышникова ЛА, Шурыгин АА, et al. Скрининговое обследование детей и подростков III, IV и V групп здоровья с применением нового диагностического теста. Туберкулез И Болезни Легких. 2015;0:40–1.
  99. Kwiatkowska B, Filipowicz‑Sosnowska A. Reactive arthritis. Pol Arch Intern Med. 2009;119:60–6. doi: 10.20452/pamw.606
  100. Allen V, Longley N. Infections in immunosuppressed travellers with autoimmune inflammatory diseases—a narrative review and advice for clinical practice. Rheumatology. 2021;60:3969–76. doi: 10.1093/rheumatology/keab445
  101. Whyte LA, Al-Araji RA, McLoughlin LM. Guidelines for the management of acute gastroenteritis in children in Europe. Arch Dis Child - Educ Pract Ed. 2015;100:308–12. doi: 10.1136/archdischild-2014-307253
  102. Bockemühl, J., Roggentin, P. Enterale Yersiniosen. Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz 47, 685–691 (2004). https://doi.org/10.1007/s00103-004-0865-9
  103. Katz BZ, Salimi B, Kim S, et al. Epstein-Barr virus burden in adolescents with systemic lupus erythematosus: Pediatr Infect Dis J. 2001;20:148–53. doi: 10.1097/00006454-200102000-00006
  104. Aygun D, Kuskucu MA, Sahin S, et al. Epstein–Barr virus, cytomegalovirus and BK polyomavirus burden in juvenile systemic lupus erythematosus: correlation with clinical and laboratory indices of disease activity. Lupus. 2020;29:1263–9. doi: 10.1177/0961203320940029
  105. Chen X, Li H, Wu C, et al. Epstein‒Barr virus and human herpesvirus 6 infection in patients with systemic lupus erythematosus. Virol J. 2023;20:29. doi: 10.1186/s12985-023-01987-3
  106. Shi T, Huang L, Tian J. Prevalence of Epstein-Barr Viral DNA among children at a single hospital in Suzhou, China. J Pediatr (Rio J). 2022;98:142–6. doi: 10.1016/j.jped.2021.05.006
  107. Rozenblyum EV, Levy DM, Allen U, et al. Cytomegalovirus in pediatric systemic lupus erythematosus: prevalence and clinical manifestations. Lupus. 2015;24:730–5. doi: 10.1177/0961203314565443
  108. Rozenblyum EV, Allen UD, Silverman ED, et al. Cytomegalovirus infection in childhood-onset systemic lupus erythematosus. Int J Clin Rheumatol. 2013;8:137–46. doi: 10.2217/ijr.12.82
  109. Strick LB, Wald A. Diagnostics for Herpes Simplex Virus: Is PCR the New Gold Standard? Mol Diagn Ther. 2006;10:17–28. doi: 10.1007/BF03256439
  110. Engelmann I, Petzold DR, Kosinska A, et al. Rapid quantitative PCR assays for the simultaneous detection of herpes simplex virus, varicella zoster virus, cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6 DNA in blood and other clinical specimens. J Med Virol. 2008;80:467–77. doi: 10.1002/jmv.21095
  111. Kazyra IA, Rubanik LV, Sukala AV, et al. Оцінка вкладу герпесвірусної інфекції в розвиток і прогресування хронічних гломерулярних хвороб у дітей. CHILDS Health. 2021;13:621–8. doi: 10.22141/2224-0551.13.7.2018.148913
  112. Widasmara D, Firdausiya F. Disseminated Herpes Zoster on a Child with Systemic Lupus Erythematosus and Lupus Nephritis. Infect Drug Resist. 2021;Volume 14:2777–85. doi: 10.2147/IDR.S314220
  113. Kapoor T, Mahadeshwar P, Bhandari B, Li J, Bathon J, Nguyen S, Askanase AD. Herpetic Viruses in Lupus [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/herpetic-viruses-in-lupus/. Accessed July 25, 2024.
  114. Jog NR, Young KA, Munroe ME, et al. Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. Ann Rheum Dis. 2019;78:1235–41. doi: 10.1136/annrheumdis-2019-215361
  115. Li Z-X, Zeng S, Wu H-X, et al. The risk of systemic lupus erythematosus associated with Epstein–Barr virus infection: a systematic review and meta-analysis. Clin Exp Med. 2019;19:23–36. doi: 10.1007/s10238-018-0535-0
  116. Rasmussen N, Draborg A, Nielsen C, et al. Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus erythematosus patients. Scand J Rheumatol. 2015;44:143–9. doi: 10.3109/03009742.2014.973061
  117. Alexeeva EI, Dvoryakovskaya TM, Nikishina IP, et al. Systemic lupus erythematosus: clinical recommendations. Part 2. Curr Pediatr. 2018;17:110–25. doi: 10.15690/vsp.v17i2.1877
  118. Cascio A., Colomba C. Childhood Mediterranean visceral leishmaniasis //Le Infezioni in Medicina. – 2003. – Т. 11. – №. 1. – С. 5-10.
  119. Wang S, Chen Y, Xu X, et al. Prevalence of hepatitis B virus and hepatitis C virus infection in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Oncotarget. 2017;8:102437–45. doi: 10.18632/oncotarget.22261
  120. González CM, López-Longo FJ, Samson J, et al. Antiribonucleoprotein Antibodies in Children with HIV Infection: A Comparative Study with Childhood-Onset Systemic Lupus Erythematosus. AIDS Patient Care STDs. 1998;12:21–8. doi: 10.1089/apc.1998.12.21
  121. Chalom EC, Rezaee F, Mendelson J. Pediatric patient with systemic lupus erythematosus & congenital acquired immunodeficiency syndrome: An unusual case and a review of the literature. Pediatr Rheumatol. 2008;6:7. doi: 10.1186/1546-0096-6-7
  122. Robinson JL, Lee BE, Kothapalli S, et al. Use of Throat Swab or Saliva Specimens for Detection of Respiratory Viruses in Children. Clin Infect Dis. 2008;46:e61–4. doi: 10.1086/529386
  123. Levy DM, Kamphuis S. Systemic Lupus Erythematosus in Children and Adolescents. Pediatr Clin North Am. 2012;59:345–64. doi: 10.1016/j.pcl.2012.03.007
  124. Chien Y-L, Huang F-L, Huang C-M, et al. Clinical approach to fever of unknown origin in children. J Microbiol Immunol Infect. 2017;50:893–8. doi: 10.1016/j.jmii.2015.08.007
  125. Ahmadinejad Z, Mansori S, Ziaee V, et al. Periodic Fever: a review on clinical, management and guideline for Iranian patients - part I. Iran J Pediatr 2014;24:1–13.
  126. Weiss SL, Peters MJ, Alhazzani W, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Intensive Care Med. 2020;46:10–67. doi: 10.1007/s00134-019-05878-6
  127. Howell MD, Davis AM. Management of Sepsis and Septic Shock. 2017;2.
  128. Illescas‐Montes R, Corona‐Castro CC, Melguizo‐Rodríguez L, et al. Infectious processes and systemic lupus erythematosus. Immunology. 2019;158:153–60. doi: 10.1111/imm.13103
  129. Ören H, Cingöz I, Duman M, et al. Disseminated intravascular coagulation in pediatric patients: clinical and Laboratory Features and Prognostic Factors Influencing the Survival. Pediatr Hematol Oncol. 2005;22:679–88. doi: 10.1080/08880010500278749
  130. Skare T, Picelli L, Dos Santos TAG, et al. Direct antiglobulin (Coombs) test in systemic lupus erythematosus patients. Clin Rheumatol. 2017;36:2141–4. doi: 10.1007/s10067-017-3778-3
  131. Nik A, Mirfeizi Z, Rezaieyazdi Z, et al. ABO and Rh blood groups in patients with Lupus and Rheumatoid Arthritis. Casp J Intern Med. 2021;12. doi: 10.22088/cjim.12.4.568
  132. Nakamura N, Fujita T, Nakamura M, et al. Systemic lupus erythematosus and blood type. The Lancet. 2006;368:1022. doi: 10.1016/S0140-6736(06)69417-8
  133. Coovadia HM, Hussain A, Mwelase LH. Systemic lupus erythematosus in a black South African child. First documented case report. South Afr Med J Suid-Afr Tydskr Vir Geneeskd. 1991;79:101–3.
  134. Mohammed AGaffarA, Alghamdi AA, ALjahlan MA, et al. Echocardiographic findings in asymptomatic systemic lupus erythematosus patients. Clin Rheumatol. 2017;36:563–8. doi: 10.1007/s10067-016-3486-4
  135. Mohamed AAA, Hammam N, El Zohri MH, et al. Cardiac Manifestations in Systemic Lupus Erythematosus: Clinical Correlates of Subclinical Echocardiographic Features. BioMed Res Int. 2019;2019:1–8. doi: 10.1155/2019/2437105
  136. Tani C, Carli L, Stagnaro C, Elefante E, Signorini V, Balestri F, Delle Sedie A, Mosca M. Imaging of joints in systemic lupus erythematosus. Clin Exp Rheumatol. 2018 Sep-Oct;36 Suppl 114(5):68-73. Epub 2018 Oct 1. PMID: 30296972.
  137. Di Matteo A, Isidori M, Corradini D, et al. Ultrasound in the assessment of musculoskeletal involvement in systemic lupus erythematosus: state of the art and perspectives. Lupus. 2019;28:583–90. doi: 10.1177/0961203319834671
  138. Di Matteo A, Smerilli G, Cipolletta E, et al. Imaging of Joint and Soft Tissue Involvement in Systemic Lupus Erythematosus. Curr Rheumatol Rep. 2021;23:73. doi: 10.1007/s11926-021-01040-8
  139. Munir S, Patil K, Miller E, et al. Juvenile Idiopathic Arthritis of the Axial Joints: A Systematic Review of the Diagnostic Accuracy and Predictive Value of Conventional MRI. Am J Roentgenol. 2014;202:199–210. doi: 10.2214/AJR.12.10475
  140. Li Z, Xu D, Wang Z, et al. Gastrointestinal system involvement in systemic lupus erythematosus. Lupus. 2017;26:1127–38. doi: 10.1177/0961203317707825
  141. Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8:1179–207. doi: 10.1016/j.crohns.2014.04.005
  142. Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care—An Evidence-based Guideline From European Crohn’s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67:257–91. doi: 10.1097/MPG.0000000000002035
  143. Sierra D, Wood M, Kolli S, et al. Pediatric Gastritis, Gastropathy, and Peptic Ulcer Disease. Pediatr Rev. 2018;39:542–9. doi: 10.1542/pir.2017-0234
  144. Tutar E, Kutluk G, Bayrak NA, et al. What is the diagnostic utility of endoscopic scoring systems in children? Turk J Gastroenterol. 2009;24:22–9. doi: 10.4318/tjg.2013.0700
  145. Frittoli RB, Vivaldo JF, Costallat LTL, et al. Gastrointestinal involvement in systemic lupus erythematosus: A systematic review. J Transl Autoimmun. 2021;4:100106. doi: 10.1016/j.jtauto.2021.100106
  146. Kröner PT, Tolaymat OA, Bowman AW, et al. Gastrointestinal Manifestations of Rheumatological Diseases. Am J Gastroenterol. 2019;114:1441–54. doi: 10.14309/ajg.0000000000000260
  147. Kalman RS, Wolf JL. Gastrointestinal Manifestations of Systemic Lupus Erythematosus. In: Schur PH, Massarotti EM, eds. Lupus Erythematosus. New York, NY: Springer New York 2012:153–68.
  148. Lopez Velazquez M, Highland KB. Pulmonary manifestations of systemic lupus erythematosus and Sjögren’s syndrome. Curr Opin Rheumatol. 2018;30:449–64. doi: 10.1097/BOR.0000000000000531
  149. Santamaria‐Alza Y, Sanchez‐Bautista J, Fajardo‐Rivero JE, et al. Acute respiratory involvement in Colombian patients with systemic lupus erythematosus undergoing chest computed tomography. Int J Rheum Dis. 2019;22:1825–31. doi: 10.1111/1756-185X.13686
  150. Enomoto N, Egashira R, Tabata K, et al. Analysis of systemic lupus erythematosus-related interstitial pneumonia: a retrospective multicentre study. Sci Rep. 2019;9:7355. doi: 10.1038/s41598-019-43782-7
  151. Allen-Rhoades W, Whittle SB, Rainusso N. Pediatric Solid Tumors in Children and Adolescents: An Overview. Pediatr Rev. 2018;39:444–53. doi: 10.1542/pir.2017-0268
  152. García-Basteiro AL, DiNardo A, Saavedra B, et al. Point of care diagnostics for tuberculosis. Pulmonology. 2018;24:73–85. doi: 10.1016/j.rppnen.2017.12.002
  153. Liu J, Hu S, Niu M, et al. Lung cancer mimicking systemic lupus erythematosus: case-based review. Rheumatol Int. 2021;41:981–6. doi: 10.1007/s00296-019-04356-y
  154. Record JL, Beukelman T, Cron RQ. High prevalence of myositis in a southeastern United States pediatric systemic lupus erythematosus cohort. Pediatr Rheumatol. 2011;9:20. doi: 10.1186/1546-0096-9-20
  155. Lin K-H, Kao J-K. Overlap syndrome in a 12-year-old girl with systemic lupus erythematosus and anti-oj antibody-positive polymyositis: a case report. Pediatr Rheumatol. 2022;20:92. doi: 10.1186/s12969-022-00753-z
  156. Cao Z-Y, Wang N, Jia J-T, et al. Abnormal topological organization in systemic lupus erythematosus: a resting-state functional magnetic resonance imaging analysis. Brain Imaging Behav. 2021;15:14–24. doi: 10.1007/s11682-019-00228-y
  157. Mavrogeni S, Koutsogeorgopoulou L, Dimitroulas T, et al. Combined Brain/Heart Magnetic Resonance Imaging in Systemic Lupus Erythematosus. Curr Cardiol Rev. 2020;16:178–86. doi: 10.2174/1573403X15666190801122105
  158. Fonseca MB, Gomes FHR, Valera ET, et al. Signs and symptoms of rheumatic diseases as first manifestation of pediatric cancer: diagnosis and prognosis implications. Rev Bras Reumatol Engl Ed. 2017;57:330–7. doi: 10.1016/j.rbre.2017.01.007
  159. Alias A, Rodriguez EJ, Bateman HE, et al. Rheumatology and oncology: an updated review of rheumatic manifestations of malignancy and anti-neoplastictherapy. Bull NYU Hosp Jt Dis. 2012;70:109–14.
  160. Goh YP, Naidoo P, Ngian G-S. Imaging of systemic lupus erythematosus. Part II: Gastrointestinal, renal, and musculoskeletal manifestations. Clin Radiol. 2013;68:192–202. doi: 10.1016/j.crad.2012.06.109
  161. Fotis L, Baszis KW, French AR, et al. Mesenteric vasculitis in children with systemic lupus erythematosus. Clin Rheumatol. 2016;35:785–93. doi: 10.1007/s10067-015-2892-3
  162. Lalani TA, Kanne JP, Hatfield GA, et al. Imaging Findings in Systemic Lupus Erythematosus. RadioGraphics. 2004;24:1069–86. doi: 10.1148/rg.244985082
  163. Williams JN, Speyer CB, Kreps DJ, et al. Spinal cord syndromes in patients with systemic lupus erythematosus: differentiating lupus myelitis, neuromyelitis optica, and multiple sclerosis. Lupus. 2019;28:1656–62. doi: 10.1177/0961203319886103
  164. Mackay M, Tang CC, Vo A. Advanced neuroimaging in neuropsychiatric systemic lupus erythematosus. Curr Opin Neurol. 2020;33:353–61. doi: 10.1097/WCO.0000000000000822
  165. Loctin A, Bailly F, Laroche D, et al. Clinical interest of bone marrow aspiration in rheumatology: a practice-based observational study of 257 bone marrow aspirations. Clin Rheumatol. 2013;32:115–21. doi: 10.1007/s10067-012-2097-y
  166. Quintero-Del-Rio AI, Miller V. Neurologic Symptoms in Children With Systemic Lupus Erythematosus. J Child Neurol. 2000;15:803–7. doi: 10.1177/088307380001501207
  167. Gokce M, Bilginer Y, Besbas N, et al. Hematological features of pediatric systemic lupus erythematosus: suggesting management strategies in children. Lupus. 2012;21:878–84. doi: 10.1177/0961203312443721
  168. Zucker EJ, Lee EY, Restrepo R, et al. Hip Disorders in Children. Am J Roentgenol. 2013;201:W776–96. doi: 10.2214/AJR.13.10623
  169. Li Q. et al. Quantifying the contribution of 18F-FDG PET to the diagnostic assessment of pediatric patients with fever of unknown origin: a systematic review and meta-analysis //Pediatric Radiology. – 2022. – С. 1-12.
  170. Colamussi P, Prandini N, Cittanti C, et al. Scintigraphy in rheumatic diseases. Best Pract Res Clin Rheumatol. 2004;18:909–26. doi: 10.1016/j.berh.2004.07.003
  171. Oh SN, Jee WH, Cho SM, et al. Osteonecrosis in patients with systemic lupus erythematosus. Clin Imaging. 2004;28:305–9. doi: 10.1016/S0899-7071(03)00192-X
  172. Ćwikła JB. New imaging techniques in reumathology: MRI, scintigraphy and PET. Pol J Radiol. 2013;78:48–56. doi: 10.12659/PJR.889138
  173. Grebenyuk V. et al. Fever of unknown origin: case reports from routine clinical practice and a review //Klinicka Mikrobiologie a Infekcni Lekarstvi. – 2021. – Т. 27. – №. 4. – С. 148-157.
  174. Cutolo M, Melsens K, Wijnant S, et al. Nailfold capillaroscopy in systemic lupus erythematosus: A systematic review and critical appraisal. Autoimmun Rev. 2018;17:344–52. doi: 10.1016/j.autrev.2017.11.025
  175. Schonenberg-Meinema D, Melsens K, Nassar-Sheikh Rashid A, et al. Capillaroscopy in childhood-onset systemic lupus erythematosus: a first systematic review. Clin Exp Rheumatol. 2020;38:350–4. doi: 10.55563/clinexprheumatol/azl2bj
  176. McDonald J, Vega-Fernandez P, Ting T. Findings and feasibility of major salivary gland ultrasound in childhood-onset systemic lupus erythematosus: a pilot study. Pediatr Rheumatol. 2021;19:73. doi: 10.1186/s12969-021-00561-x
  177. Malmström M, Seppä A, Konttinen YT, et al. Sjögren’s syndrome in systemic lupus erythematosus and rheumatoid arthritis: Immune effector cells in salivary glands. Rheumatol Int. 1983;3:1–5. doi: 10.1007/BF00541224
  178. Song GG, Lee YH. Diagnostic accuracies of sialography and salivary ultrasonography in Sjögren’s syndrome patients: a meta-analysis. Clin Exp Rheumatol. 2014;32:516–22.
  179. Takagi Y, Sasaki M, Eida S, et al. Comparison of salivary gland MRI and ultrasonography findings among patients with Sjögren’s syndrome over a wide age range. Rheumatology. 2022;61:1986–96. doi: 10.1093/rheumatology/keab560
  180. Hanly JG, O’Keeffe AG, Su L, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology. 2016;55:252–62. doi: 10.1093/rheumatology/kev311
  181. Bertsias G, Ioannidis JPA, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67:195–205. doi: 10.1136/ard.2007.070367
  182. Afonso L, Kottam A, Reddy V, et al. Echocardiography in Infective Endocarditis: State of the Art. Curr Cardiol Rep. 2017;19:127. doi: 10.1007/s11886-017-0928-9
  183. Gumireddy SR, Chaliki HP, Cummings KW, et al. Systemic Lupus Erythematosus Presenting As Constrictive Pericarditis. Circ Cardiovasc Imaging. 2020;13:e010254. doi: 10.1161/CIRCIMAGING.119.010254
  184. Аксенова ВА, Барышников ЛА, Клевно НИ, et al. Новые возможности скрининга и диагностики различных проявлений туберкулезной инфекции у детей и подростков в России. Вопросы Современной Педиатрии 2011;10:16–22.
  185. De Andrade FA, Guimarães Moreira Balbi G, Bortoloti De Azevedo LG, et al. Neuro-ophthalmologic manifestations in systemic lupus erythematosus. Lupus. 2017;26:522–8. doi: 10.1177/0961203316683265
  186. Preble JM, Silpa-archa S, Foster CS. Ocular involvement in systemic lupus erythematosus: Curr Opin Ophthalmol. 2015;26:540–5. doi: 10.1097/ICU.0000000000000209
  187. Shoughy SS, Tabbara KF. Ocular findings in systemic lupus erythematosus. Saudi J Ophthalmol. 2016;30:117–21. doi: 10.1016/j.sjopt.2016.02.001
  188. Papagiannuli E, Rhodes B, Wallace GR, et al. Systemic lupus erythematosus: An update for ophthalmologists. Surv Ophthalmol. 2016;61:65–82. doi: 10.1016/j.survophthal.2015.06.003
  189. Albilia JB, Lam DK, Clokie CML, et al. Systemic lupus erythematosus: a review for dentists. J Can Dent Assoc. 2007;73:823–8.
  190. Mays JW, Sarmadi M, Moutsopoulos NM. Oral Manifestations of Systemic Autoimmune and Inflammatory Diseases: Diagnosis and Clinical Management. J Evid Based Dent Pract. 2012;12:265–82. doi: 10.1016/S1532-3382(12)70051-9
  191. Meszaros ZS, Perl A, Faraone SV. Psychiatric Symptoms in Systemic Lupus Erythematosus: A Systematic Review. J Clin Psychiatry. 2012;73:993–1001. doi: 10.4088/JCP.11r07425
  192. Bowman CA, Linthicum FH, Nelson RA, et al. Sensorineural Hearing Loss Associated with Systemic Lupus Erythematosus. Otolaryngol Neck Surg. 1986;94:197–204. doi: 10.1177/019459988609400212
  193. Harari S, Paciocco G, Aramu S. Ear and nose involvement in systemic diseases. Monaldi Arch Chest Dis Arch Monaldi Mal Torace. 2000;55:466–70.
  194. Hashkes PJ, Laxer RM, Simon A, editors. Textbook of Autoinflammation. Cham: Springer International Publishing 2019.
  195. Gualtierotti R, Parisi M, Ingegnoli F. Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview. Adv Ther. 2018;35:439–56. doi: 10.1007/s12325-018-0686-0
  196. Ben-Menachem E. Systemic Lupus Erythematosus: A Review for Anesthesiologists. Anesth Analg. 2010;111:665–76. doi: 10.1213/ANE.0b013e3181e8138e
  197. Голуб И. Е., Сорокина Л. В. Избранные вопросы по общей анестезиологии (методические рекомендации для клинических ординаторов, с правом переиздания). – 2005.
  198. Röher K, Trieschmann U, Leister N. Anästhesie und Analgosedierung für diagnostische Eingriffe bei Kindern. AINS - Anästhesiol · Intensivmed · Notfallmedizin · Schmerzther. 2023;58:409–20. doi: 10.1055/a-1925-7009
  199. Dumas G, Arabi YM, Bartz R, et al. Diagnosis and management of autoimmune diseases in the ICU. Intensive Care Med. 2024;50:17–35. doi: 10.1007/s00134-023-07266-7
  200. Janssen NM, Karnad DR, Guntupalli KK. Rheumatologic diseases in the intensive care unit: epidemiology, clinical approach, management, and outcome. Crit Care Clin. 2002;18:729–48. doi: 10.1016/S0749-0704(02)00025-8
  201. Hsieh L-F, Mao H-F, Lu C-C, et al. Rheumatologic Rehabilitation. Braddom’s Physical Medicine and Rehabilitation. Elsevier 2021:606-626.e1.
  202. Fangtham M, Kasturi S, Bannuru RR, et al. Non-pharmacologic therapies for systemic lupus erythematosus. Lupus. 2019;28:703–12. doi: 10.1177/0961203319841435
  203. Quilter M, Hiraki L, Korczak D. Depressive and anxiety symptom prevalence in childhood-onset systemic lupus erythematosus: A systematic review. Lupus. 2019;28:878–87. doi: 10.1177/0961203319853621
  204. Amezcua‐Guerra LM, Higuera‐Ortiz V, Arteaga‐García U, et al. Performance of the 2012 Systemic Lupus International Collaborating Clinics and the 1997 American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Real‐Life Scenario. Arthritis Care Res. 2015;67:437–41. doi: 10.1002/acr.22422
  205. Yu C, Gershwin ME, Chang C. Diagnostic criteria for systemic lupus erythematosus: A critical review. J Autoimmun. 2014;48–49:10–3. doi: 10.1016/j.jaut.2014.01.004
  206. Miyamae T, Kawabe T. Non-Criteria Manifestations of Juvenile Antiphospholipid Syndrome. J Clin Med. 2021;10:1240. doi: 10.3390/jcm10061240
  207. Tarango C, Palumbo JS. Antiphospholipid syndrome in pediatric patients. Curr Opin Hematol. 2019;26:366–71. doi: 10.1097/MOH.0000000000000523
  208. Vreede AP, Bockenstedt PL, Knight JS. Antiphospholipid syndrome: an update for clinicians and scientists. Curr Opin Rheumatol. 2017;29:458–66. doi: 10.1097/BOR.0000000000000410
  209. Go EJL, O’Neil KM. The catastrophic antiphospholipid syndrome in children. Curr Opin Rheumatol. 2017;29:516–22. doi: 10.1097/BOR.0000000000000426
  210. Chaturvedi S, McCrae KR. Diagnosis and management of the antiphospholipid syndrome. Blood Rev. 2017;31:406–17. doi: 10.1016/j.blre.2017.07.006
  211. Gerosa M, Meroni PL, Erkan D. Recognition and management of antiphospholipid syndrome. Curr Opin Rheumatol. 2016;28:51–9. doi: 10.1097/BOR.0000000000000240
  212. Uthman I, Khamashta M. The abdominal manifestations of the antiphospholipid syndrome. Rheumatology. 2007;46:1641–7. doi: 10.1093/rheumatology/kem158
  213. Tektonidou MG, Moutsopoulos HM. Osteoarticular Manifestations of Antiphospholipid Syndrome. In: Khamashta MA, ed. Hughes Syndrome. London: Springer-Verlag 2006:127–39.
  214. Turrent-Carriles A, Herrera-Félix JP, Amigo M-C. Renal Involvement in Antiphospholipid Syndrome. Front Immunol. 2018;9:1008. doi: 10.3389/fimmu.2018.01008
  215. Rosina S, Chighizola CB, Ravelli A, et al. Pediatric Antiphospholipid Syndrome: from Pathogenesis to Clinical Management. Curr Rheumatol Rep. 2021;23:10. doi: 10.1007/s11926-020-00976-7
  216. Park JM, Shin JI, Shin YH, et al. Catastrophic antiphospholipid syndrome in a 7-year-old girl. Clin Rheumatol. 2007;26:1011–3. doi: 10.1007/s10067-006-0251-0
  217. Tsirpanlis G, Moustakas G, Sakka E, et al. Catastrophic antiphospholipid syndrome in a 14-year-old child. Pediatr Nephrol. 2005;20:519–21. doi: 10.1007/s00467-004-1761-0
  218. Ravelli A, Martini A. Antiphospholipid Syndrome in Pediatrics. Rheum Dis Clin N Am. 2007;33:499–523. doi: 10.1016/j.rdc.2007.07.001
  219. Liu L, Liu L, Zhang L, et al. Case Report: A case of recurrent thrombosis in pediatric antiphospholipid syndrome associated with pediatric onset systemic lupus. Front Pediatr. 2023;10:1004053. doi: 10.3389/fped.2022.1004053
  220. Enocsson H, Karlsson J, Li H-Y, et al. The Complex Role of C-Reactive Protein in Systemic Lupus Erythematosus. J Clin Med. 2021;10:5837. doi: 10.3390/jcm10245837
  221. Yuan W-H, Liu H-C, Zeng L-K, et al. [Change of Thrombelastography in Children’s DIC and Analysis of Its Sensitivity and Specificity for Diagnosis of DIC]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2017;25:847–52. doi:10.7534/j.issn.1009-2137.2017.03.039.
  222. Hasegawa M, Yamashita J, Yamashima T, et al. Spinal cord infarction associated with primary antiphospholipid syndrome in a young child: Case report. J Neurosurg. 1993;79:446–50. doi: 10.3171/jns.1993.79.3.0446
  223. Rodrigues CEM, De Carvalho JF. Clinical, Radiologic, and Therapeutic Analysis of 14 Patients with Transverse Myelitis Associated with Antiphospholipid Syndrome: Report of 4 Cases and Review of the Literature. Semin Arthritis Rheum. 2011;40:349–57. doi: 10.1016/j.semarthrit.2010.05.004
  224. Rodrigues CEM, Carvalho JF, Shoenfeld Y. Neurological manifestations of antiphospholipid syndrome. Eur J Clin Invest. 2010;40:350–9. doi: 10.1111/j.1365-2362.2010.02263.x
  225. Fleetwood T, Cantello R, Comi C. Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy. Front Neurol. 2018;9:1001. doi: 10.3389/fneur.2018.01001
  226. Taraborelli M, Leuenberger L, Lazzaroni MG, et al. The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus. Lupus. 2016;25:1365–8. doi: 10.1177/0961203316637431
  227. Montes De Oca MA, Babron MC, Bletry O, et al. Thrombosis in systemic lupus erythematosus: a French collaborative study. Arch Dis Child. 1991;66:713–7. doi: 10.1136/adc.66.6.713
  228. Soybilgic A, Avcin T. Pediatric APS: State of the Art. Curr Rheumatol Rep. 2020;22:9. doi: 10.1007/s11926-020-0887-9
  229. Naveen R, Jain A, Muhammed H, et al. Macrophage activation syndrome in systemic lupus erythematosus and systemic-onset juvenile idiopathic arthritis: a retrospective study of similarities and dissimilarities. Rheumatol Int. 2021;41:625–31. doi: 10.1007/s00296-020-04763-6
  230. Gavand P-E, Serio I, Arnaud L, et al. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients. Autoimmun Rev. 2017;16:743–9. doi: 10.1016/j.autrev.2017.05.010
  231. Vilaiyuk S, Sirachainan N, Wanitkun S, et al. Recurrent macrophage activation syndrome as the primary manifestation in systemic lupus erythematosus and the benefit of serial ferritin measurements: a case-based review. Clin Rheumatol. 2013;32:899–904. doi: 10.1007/s10067-013-2227-1
  232. Parodi A, Davì S, Pringe AB, et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: A multinational multicenter study of thirty‐eight patients. Arthritis Rheum. 2009;60:3388–99. doi: 10.1002/art.24883
  233. Ravelli A, Davì S, Minoia F, et al. Macrophage Activation Syndrome. Hematol Oncol Clin North Am. 2015;29:927–41. doi: 10.1016/j.hoc.2015.06.010
  234. Lehmberg K, Pink I, Eulenburg C, et al. Differentiating Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis from Other Forms of Hemophagocytic Lymphohistiocytosis. J Pediatr. 2013;162:1245–51. doi: 10.1016/j.jpeds.2012.11.081
  235. Ke Y, Lv C, Xuan W, et al. Clinical analysis of macrophage activation syndrome in adult rheumatic disease: A multicenter retrospective study. Int J Rheum Dis. 2020;23:1488–96. doi: 10.1111/1756-185X.13955
  236. Тепаев РФ. Синдром диссеминированного внутрисосудистого свертывания у детей. Диагностика и лечение. Педиатрическая Фармакология 2010;7:27–31.
  237. Rajagopal R, Thachil J, Monagle P. Disseminated intravascular coagulation in paediatrics. Arch Dis Child. 2017;102:187–93. doi: 10.1136/archdischild-2016-311053
  238. Gliwińska A, Bjanid O, Adamczyk P, et al. A rare complication of systemic lupus erythematosus in a 9-year-old girl: Answers. Pediatr Nephrol. 2020;35:781–5. doi: 10.1007/s00467-019-04412-6
  239. Avčin T, Tse SML, Schneider R, et al. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr. 2006;148:683–6. doi: 10.1016/j.jpeds.2005.12.070
  240. Ansuini V, Rigante D, Esposito S. Debate around infection-dependent hemophagocytic syndrome in paediatrics. BMC Infect Dis. 2013;13:15. doi: 10.1186/1471-2334-13-15
  241. D’Errico MM, Cuoco F, Biancardi C, et al. YIM-P58. Macrophage activation syndrome: the role of infectious triggers. Pediatr Rheumatol. 2014;12:Y5, 1546-0096-12-S1-Y5. doi: 10.1186/1546-0096-12-S1-Y5
  242. Vince A, Dusek D. Imunosupresija i virusne infekcije u reumatskim bolestima [Immunosupression and viral infections in rheumatic diseases]. Reumatizam. 2007;54(2):58-62. Croatian. PMID: 18351141.
  243. Waris ME, Toikka P, Saarinen T, et al. Diagnosis of Mycoplasma pneumoniae Pneumonia in Children. J Clin Microbiol. 1998;36:3155–9. doi: 10.1128/JCM.36.11.3155-3159.1998
  244. Department of Microbiology, Maulana Azad Medical College, India, Kumar S, Kumar S, et al. Mycoplasma Pneumoniae as a Causative Agent of Community-Acquired Lower Respiratory Tract Infections in Children. Ann Pediatr Child Health. 2023;11:1–4. doi: 10.47739/2373-9312.pediatrics.1325
  245. Eisenstein EM, Wolf DG. RCevyietwomegalovirus infection in pediatric rheumatic diseases: a review. 2010;7.
  246. Hines MR, von Bahr Greenwood T, Beutel G, et al. Consensus-Based Guidelines for the Recognition, Diagnosis, and Management of Hemophagocytic Lymphohistiocytosis in Critically Ill Children and Adults. Crit Care Med. 2022;50:860–72. doi: 10.1097/CCM.0000000000005361
  247. Eisenstein EM, Wolf DG. Cytomegalovirus infection in pediatric rheumatic diseases: a review. Pediatr Rheumatol. 2010;8:17. doi: 10.1186/1546-0096-8-17
  248. for the Paediatric Rheumatology International Trials Organisation (PRINTO), Giancane G, Swart JF, et al. Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. Arthritis Res Ther. 2020;22:71. doi: 10.1186/s13075-020-02167-2
  249. Houen G, Trier NH. Epstein-Barr Virus and Systemic Autoimmune Diseases. Front Immunol. 2021;11:587380. doi: 10.3389/fimmu.2020.587380
  250. Nadimpalli S, Foca M, Satwani P, et al. Diagnostic yield of bronchoalveolar lavage in immunocompromised children with malignant and non-malignant disorders: BAL in Immunocompromised Children. Pediatr Pulmonol. 2017;52:820–6. doi: 10.1002/ppul.23644
  251. Ers. Bronchoalveolar lavage in children. Eur Respir J. 2000;15:217–31. doi: 10.1183/09031936.00.15121700
  252. Amanati A, Karimi A, Fahimzad A, et al. Prevalence of Human Herpes Viruses in Bronchoalveolar Lavage of Critically Ill Children Undergoing Mechanical Ventilation at a Pediatric Intensive Care Unit. Arch Pediatr Infect Dis. 2018;6. doi: 10.5812/pedinfect.12685
  253. Wong JCP, Hon KLE, Leung KKY, et al. Diagnostic Yield of Bronchoalveolar Lavage in Immunocompromised Children. J Trop Pediatr. 2021;67:fmaa131. doi: 10.1093/tropej/fmaa131
  254. Eroglu‐Ertugrul NG, Yalcin E, Oguz B, et al. The value of flexible bronchoscopy in pulmonary infections of immunosuppressed children. Clin Respir J. 2020;14:78–84. doi: 10.1111/crj.13103
  255. Gonski K, Cohn R, Widger J, et al. Utility of bronchoscopy in immunocompromised paediatric patients: Systematic review. Paediatr Respir Rev. 2020;34:24–34. doi: 10.1016/j.prrv.2020.02.003
  256. Özkoç S, Bayram Deli̇Baş S. Investigation of Pneumocystis jirovecii Pneumonia and Colonization in Iatrogenically Immunosuppressed and Immunocompetent Patients. Mikrobiyol Bul. 2015;49:221–30. doi: 10.5578/mb.9344
  257. Lachant DJ, Croft DP, McGrane Minton H, et al. The clinical impact of pneumocystis and viral PCR testing on bronchoalveolar lavage in immunosuppressed patients. Respir Med. 2018;145:35–40. doi: 10.1016/j.rmed.2018.10.021
  258. Varadaraju S, Khandelwal P, Sankar J, et al. Multiple opportunistic infection-associated hemophagocytic lymphohistiocytosis in nephrotic syndrome: A case report. J Pediatr Crit Care. 2021;8:295. doi: 10.4103/jpcc.jpcc_64_21
  259. Weyant RB, Kabbani D, Doucette K, et al. Pneumocystis jirovecii: a review with a focus on prevention and treatment. Expert Opin Pharmacother. 2021;22:1579–92. doi: 10.1080/14656566.2021.1915989
  260. García-Moreno J, Melendo-Pérez S, Martín-Gómez MT, et al. Pneumocystis jirovecii pneumonia in children. A retrospective study in a single center over three decades. Enfermedades Infecc Microbiol Clínica. 2020;38:111–8. doi: 10.1016/j.eimc.2019.05.005
  261. White PL, Price JS, Backx M. Pneumocystis jirovecii Pneumonia: Epidemiology, Clinical Manifestation and Diagnosis. Curr Fungal Infect Rep. 2019;13:260–73. doi: 10.1007/s12281-019-00349-3
  262. Morris A, Norris KA. Colonization by Pneumocystis jirovecii and Its Role in Disease. Clin Microbiol Rev. 2012;25:297–317. doi: 10.1128/CMR.00013-12
  263. Vega-Briceño LE, Holmgren NL, Bertrand P, et al. Utility of Bronchoalveolar Lavage in Immunocompromised Children: Diagnostic Yield and Complications. Arch Bronconeumol Engl Ed. 2004;40:570–4. doi: 10.1016/S1579-2129(06)60377-7
  264. Rayment JH, Narang I. Pulmonary Aspergillosis in a Previously Healthy 13-Year-Old Boy. Can Respir J. 2016;2016:4575942. doi: 10.1155/2016/4575942
  265. de Mol M, de Jongste JC, van Westreenen M, et al. Diagnosis of invasive pulmonary aspergillosis in children with bronchoalveolar lavage galactomannan: BAL Galactomannan Aspergillosis Children. Pediatr Pulmonol. 2013;48:789–96. doi: 10.1002/ppul.22670
  266. Silva M, Ribeiro A, Fiorot F, et al. Invasive aspergillosis: a severe infection in juvenile systemic lupus erythematosus patients. Lupus. 2012;21:1011–6. doi: 10.1177/0961203312442752
  267. Wattier R, Ramirez-Avila L. Pediatric Invasive Aspergillosis. J Fungi. 2016;2:19. doi: 10.3390/jof2020019
  268. Kashefi E, Seyedi SJ, Zomorodian K, et al. Successful treatment of pulmonary aspergillosis due to Aspergillus fumigatus in a child affected by systemic lupus erythematosus: A case report from Northeastern Iran. Clin Case Rep. 2021;9:e04248. doi: 10.1002/ccr3.4248
  269. Campos L, Omori C, Lotito A, et al. Acute pancreatitis in juvenile systemic lupus erythematosus: a manifestation of macrophage activation syndrome? Lupus. 2010;19:1654–8. doi: 10.1177/0961203310378863
  270. Ravelli A, Minoia F, Davì S, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2016;75:481–9. doi: 10.1136/annrheumdis-2015-208982
  271. Fayyaz A, Igoe A, Kurien BT, et al. Haematological manifestations of lupus. Lupus Sci Med. 2015;2:e000078. doi: 10.1136/lupus-2014-000078
  272. Esposito S, Bosis S, Semino M, et al. Infections and systemic lupus erythematosus. Eur J Clin Microbiol Infect Dis. 2014;33:1467–75. doi: 10.1007/s10096-014-2098-7
  273. Kim YW, Kwon BS, Lim SY, et al. Diagnostic value of bronchoalveolar lavage and bronchial washing in sputum-scarce or smear-negative cases with suspected pulmonary tuberculosis: a randomized study. Clin Microbiol Infect. 2020;26:911–6. doi: 10.1016/j.cmi.2019.11.013
  274. Daelemans, Siel & Peeters, Linde & Wachter, Elke & Malfroot, Anne. (2019). Challenges in Diagnosing Mycobacterial Infections in Children.. 21. 194-199.
  275. Wei M, Yongjie Zhao, Zhuoyu Qian, et al. Pneumonia caused by Mycobacterium tuberculosis. Microbes Infect. 2020;22:278–84. doi: 10.1016/j.micinf.2020.05.020
  276. Ciftci E. Pulmonary involvement in childhood-onset systemic lupus erythematosus: a report of five cases. Rheumatology. 2004;43:587–91. doi: 10.1093/rheumatology/keh120
  277. Sari MK, Satria CD, Arguni E. Predictors of Infection in Children with Systemic Lupus Erythematosus: A Single Center Study in Indonesia. Glob Pediatr Health. 2021;8:2333794X2110056. doi: 10.1177/2333794X211005609
  278. Xu D, Li S, Chen Z, et al. Detection of Mycoplasma pneumoniae in different respiratory specimens. Eur J Pediatr. 2011;170:851–8. doi: 10.1007/s00431-010-1360-y
  279. Copete AR, Vera C, Herrera M, et al. Mycoplasma pneumoniae in Children With and Without Community-acquired Pneumonia. What do PCR and Serology Say? Pediatr Infect Dis J. 2020;39:e104–8. doi: 10.1097/INF.0000000000002636
  280. Restrepo-Gualteros SM, Gutierrez MJ, Villamil-Osorio M, et al. Challenges and Clinical Implications of the Diagnosis of Cytomegalovirus Lung Infection in Children. Curr Infect Dis Rep. 2019;21:24. doi: 10.1007/s11908-019-0681-x
  281. Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015;14:503–9. doi: 10.1016/j.autrev.2015.01.011
  282. Handa R, Upadhyaya S, Kapoor S, et al. Tuberculosis and biologics in rheumatology: A special situation. Int J Rheum Dis. 2017;20:1313–25. doi: 10.1111/1756-185X.13129
  283. Ramos JT, Romero CA, Belda S, et al. Clinical practice update of antifungal prophylaxis in immunocompromised children. Rev Espanola Quimioter Publicacion Of Soc Espanola Quimioter 2019;32:410–25.
  284. Tragiannidis A, Kyriakidis I, Zündorf I, et al. Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors. Mycoses. 2017;60:222–9. doi: 10.1111/myc.12576
  285. Lazzerini PE, Capecchi PL, Guideri F, et al. Comparison of Frequency of Complex Ventricular Arrhythmias in Patients With Positive Versus Negative Anti-Ro/SSA and Connective Tissue Disease. Am J Cardiol. 2007;100:1029–34. doi: 10.1016/j.amjcard.2007.04.048
  286. Başaran Ö, Çetin İİ, Aydın F, et al. Heart rate variability in juvenile systemic lupus erythematosus patients. Turk J Pediatr. 2019;61:733. doi: 10.24953/turkjped.2019.05.012
  287. Carranza-Leon DA, Oeser A, Wu Q, et al. Ambulatory blood pressure in patients with systemic lupus erythematosus: Association with markers of immune activation. Lupus. 2020;29:1683–90. doi: 10.1177/0961203320951274
  288. Sharma AP, Norozi K, Filler G, et al. Diagnosis of Pediatric Hypertension: European Society of Hypertension-recommended 24-hr vs. 24-hr-day-night Ambulatory Blood Pressure thresholds. ;23.
  289. Wang L, Cao Z-M, Zhang L-L, et al. Helicobacter Pylori and Autoimmune Diseases: Involving Multiple Systems. Front Immunol. 2022;13:833424. doi: 10.3389/fimmu.2022.833424
  290. Alharbi S. Gastrointestinal Manifestations in Patients with Systemic Lupus Erythematosus. Open Access Rheumatol Res Rev. 2022;Volume 14:243–53. doi: 10.2147/OARRR.S384256
  291. Galindo-Zavala R, Bou-Torrent R, Magallares-López B, et al. Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children. Pediatr Rheumatol. 2020;18:20. doi: 10.1186/s12969-020-0411-9
  292. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: ACR guideline for glucocorticoid-induced osteoporosis prevention and treatment. Arthritis Rheumatol. 2017;69:1521–37. doi: 10.1002/art.40137
  293. Rivière E, Cohen Aubart F, Maisonobe T, et al. Clinicopathological features of multiple mononeuropathy associated with systemic lupus erythematosus: a multicenter study. J Neurol. 2017;264:1218–26. doi: 10.1007/s00415-017-8519-7
  294. Moroni G, Pasquali S, Quaglini S, et al. Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis. 1999;34:530–9. doi: 10.1016/S0272-6386(99)70082-X
  295. Vieira JP, Ortet O, Barata D, et al. Lupus myelopathy in a child. Pediatr Neurol. 2002;27:303–6. doi: 10.1016/S0887-8994(02)00439-3
  296. Sönmez HE, Karhan AN, Batu ED, et al. Gastrointestinal system manifestations in juvenile systemic lupus erythematosus. Clin Rheumatol. 2017;36:1521–6. doi: 10.1007/s10067-017-3571-3
  297. Kaegi C, Wuest B, Schreiner J, et al. Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. Front Immunol. 2019;10:1990. doi: 10.3389/fimmu.2019.01990
  298. Aparicio-Soto M, Sánchez-Hidalgo M, Alarcón-de-la-Lastra C. An update on diet and nutritional factors in systemic lupus erythematosus management. Nutr Res Rev. 2017;30:118–37. doi: 10.1017/S0954422417000026
  299. Constantin M, Nita I, Olteanu R, et al. Significance and impact of dietary factors on systemic lupus erythematosus pathogenesis (Review). Exp Ther Med. Published Online First: 16 November 2018. doi: 10.3892/etm.2018.6986
  300. Sherman JM, Sood SK. Current challenges in the diagnosis and management of fever. Curr Opin Pediatr. 2012;24:400–6. doi: 10.1097/MOP.0b013e32835333e3
  301. Carreño L, López-Longo FJ, González CM, Monteagudo I. Treatment options for juvenile-onset systemic lupus erythematosus. Paediatr Drugs. 2002;4(4):241-56. doi: 10.2165/00128072-200204040-00004. PMID: 11960513
  302. Thakral A, Klein-Gitelman MS. An Update on Treatment and Management of Pediatric Systemic Lupus Erythematosus. Rheumatol Ther. 2016;3:209–19. doi: 10.1007/s40744-016-0044-0
  303. Horizon AA, Wallace DJ. Risk:benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Expert Opin Drug Saf. 2004;3:273–8. doi: 10.1517/14740338.3.4.273
  304. Ardoin SP. Transitions in Rheumatic Disease. Pediatr Clin North Am. 2018;65:867–83. doi: 10.1016/j.pcl.2018.04.007
  305. Ardoin SP, Schanberg LE. The management of pediatric systemic lupus erythematosus. Nat Clin Pract Rheumatol. 2005;1:82–92. doi: 10.1038/ncprheum0046
  306. Gupta P, Sachdev HP. Safety of oral use of nimesulide in children: systematic review of randomized controlled trials. Indian Pediatr. 2003 Jun;40(6):518-31. PMID: 12824661.
  307. Guillaume-Czitrom S. Les anti-inflammatoires non stéroïdiens dans les rhumatismes inflammatoires chroniques de l’enfant [Non -steroidal anti-inflammatory drugs in chronic inflammatory arthritis in children]. La Lettre du Rhumatologue №379-380 - février-mars 2012.
  308. Иосифовна АЕ, С.и В. Оценка эффективности, переносимости и безопасности нимесулида у детей с ювенильным артритом. Вопросы Современной Педиатрии. 2007;6:76–80.
  309. Клинический протокол диагностики и лечения Системная красная волчанка. Казахстан URL:https://nrchd.kz/files/новое%202023/КП_Системная%20красная%20волчанка%20у%20детей.pdf.
  310. Xiong W, Lahita RG. Pragmatic approaches to therapy for systemic lupus erythematosus. Nat Rev Rheumatol. 2014;10:97–107. doi: 10.1038/nrrheum.2013.157
  311. Zahr N, Urien S, Funck-Brentano C, et al. Evaluation of Hydroxychloroquine Blood Concentrations and Effects in Childhood-Onset Systemic Lupus Erythematosus. Pharmaceuticals. 2021;14:273. doi: 10.3390/ph14030273
  312. Gacem O, Abba K, Mansouri N, et al. 52 Use of corticosteroids in childhood systemic lupus erythematosus: experience from a pediatric rheumatology center. Rheumatology. 2022;61:keac496.048. doi: 10.1093/rheumatology/keac496.048
  313. Corticosteroids in Paediatric Rheumatology.  Starship clinical guidelines. URL: https://starship.org.nz/guidelines/corticosteroids-in-paediatric-rheumatology/.
  314. Brunner HI, Huggins J, Klein-Gitelman MS. Pediatric SLE—towards a comprehensive management plan. Nat Rev Rheumatol. 2011;7:225–33. doi: 10.1038/nrrheum.2011.15
  315. Xibillé-Friedmann D, Pérez-Rodríguez M, Carrillo-Vázquez S, et al. Guía de práctica clínica para el manejo del lupus eritematoso sistémico propuesta por el Colegio Mexicano de Reumatología. Reumatol Clínica. 2019;15:3–20. doi: 10.1016/j.reuma.2018.03.011
  316. Deng J, Chalhoub NE, Sherwin CM, et al. Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum. 2019;49:251–9. doi: 10.1016/j.semarthrit.2019.03.010
  317. Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. The Lancet. 2019;393:2344–58. doi: 10.1016/S0140-6736(19)30546-X
  318. Téllez Arévalo AM, Quaye A, Rojas-Rodríguez LC, et al. Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety. Medicina (Mex). 2022;59:56. doi: 10.3390/medicina59010056
  319. The Leeds Children’s Hospital Administration Guide Intravenous methotrexate for Paediatric Rheumatology. URL https://www.leedsformulary.nhs.uk/docs/PaediatricIVMTXprotocol.pdf.
  320. BNSSG Paediatric Shared Care Guidance.URL https://remedy.bnssg.icb.nhs.uk/media/3873/methotrexate-merged-scp-final-with-dermatology-update-nov-2019.pdf.
  321. Sato EI. Methotrexate therapy in systemic lupus erythematosus. Lupus. 2001;10:162–4. doi: 10.1191/096120301666080831
  322. On behalf of the Rheumatology Italian Study Group, Ferrara G, Mastrangelo G, et al. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatr Rheumatol. 2018;16:46. doi: 10.1186/s12969-018-0255-8
  323. Guti rrez-Su rez R., Burgos-Vargas R. The use of methotrexate in children with rheumatic diseases //Clinical and Experimental Rheumatology-Incl Supplements. – 2010. – Т. 28. – №. 5. – С. S122.
  324. Hunt PG, Rose CD, McIlvain-Simpson G, et al. The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. A controlled study. J Rheumatol 1997;24:2230–2.
  325. Saleh D, Grubbs H, Koritala T, et al. Tumid Lupus Erythematosus. [Updated 2023 Jun 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482515/.
  326. Methotrexate therapy/ url https://secure.library.leicestershospitals.nhs.uk/PAGL/Shared%20Documents/Methotrexate%20Therapy%20in%20Paediatric%20Rheumatology%20UHL%20Childrens%20Hospital%20Guideline.pdf.
  327. Niehues T, Lankisch P. Recommendations for the Use of Methotrexate in Juvenile Idiopathic Arthritis: Pediatr Drugs. 2006;8:347–56. doi: 10.2165/00148581-200608060-00003
  328. Lee Y, Woo J-H, Choi S, et al. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus. 2010;19:703–10. doi: 10.1177/0961203309357763
  329. Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus nephritis: The Euro‐Lupus Nephritis Trial, a randomized trial of low‐dose versus high‐dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46:2121–31. doi: 10.1002/art.10461
  330. Houssiau FA, Vasconcelos C, D’Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69:61–4. doi: 10.1136/ard.2008.102533
  331. Ogino MH, Tadi P. Cyclophosphamide. StatPearls. Treasure Island (FL): StatPearls Publishing 2024.
  332. Carless P. A. et al. Proposal for the inclusion of mesna (sodium 2-mercaptoethane sulfonate) for the prevention of ifosfamide and cyclophosphamide (oxazaphosphorine cytotoxics) induced haemorrhagic cystitis //Geneva, Switzerland: 17th Expert Committee on the Selection and Use of Essential Medicines. – 2008.
  333. Al Salloum AA. Cyclophosphamide therapy for lupus nephritis: poor renal survival in Arab children. Pediatr Nephrol. 2003;18:357–61. doi: 10.1007/s00467-003-1110-8
  334. Н.Ф. Тарасенко, М.А. Скачкова, Е.Г. Карпова. Диффузные заболевания соединительной ткани у детей.  Учебное пособие. – Оренбург, 2013. - 87 с.
  335. Brunner HI, Abud-Mendoza C, Viola DO, et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020;79:1340–8. doi: 10.1136/annrheumdis-2020-217101
  336. Van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71:1343–9. doi: 10.1136/annrheumdis-2011-200937
  337. Kraaij T, Arends EJ, Van Dam LS, et al. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results. Nephrol Dial Transplant. 2021;36:1474–83. doi: 10.1093/ndt/gfaa117
  338. Wise LM, Stohl W. Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents. Front Med. 2020;7:303. doi: 10.3389/fmed.2020.00303
  339. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918–30. doi: 10.1002/art.30613
  340. Petri MA, Van Vollenhoven RF, Buyon J, et al. Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials. Arthritis Rheum. 2013;65:2143–53. doi: 10.1002/art.37995
  341. Manzi S, Sánchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71:1833–8. doi: 10.1136/annrheumdis-2011-200831
  342. Tsang-A-Sjoe MWP, Bultink IEM. New developments in systemic lupus erythematosus. Rheumatology. 2021;60:vi21–8. doi: 10.1093/rheumatology/keab498
  343. Zhao W, Tan X, Li C, et al. Early-onset Systemic Lupus Erythematosus: A Case Serie. 2022.
  344. Levy DM, Massicotte MP, Harvey E, et al. Thromboembolism in paediatric lupus patients. Lupus. 2003;12:741–6. doi: 10.1191/0961203303lu458oa
  345. Boffa M-C, Lachassinne E. Review: Infant perinatal thrombosis and antiphospholipid antibodies: a review. Lupus. 2007;16:634–41. doi: 10.1177/0961203307079039
  346. Islabão AG, Trindade VC, Da Mota LMH, et al. Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects. Pediatr Drugs. 2022;24:13–27. doi: 10.1007/s40272-021-00484-w
  347. Гусева, Н. Вазапростан в комплексном лечении системной склеродермии и синдрома Рейно / Н. Гусева // Врач. – 2006. – № 5. – С. 46-50.
  348. Distler JHW. Primäres und sekundäres Raynaud-Phänomen. Z Für Rheumatol. 2008;67:211–9. doi: 10.1007/s00393-008-0282-9
  349. Kobayashi M, Takano K, Kamizono J, et al. A serious case of primary Raynaud’s phenomenon in an infant. Clin Case Rep. 2018;6:2089–91. doi: 10.1002/ccr3.1819
  350. Алексеева Е., Валиева С., Александров А., Хмызова С. Опыт применения алпростадила у больной системной красной волчанкой и антифосфолипидным синдромом. Педиатрическая фармакология. 2006;3(5):63-67.
  351. Lin C-Y. Improvement in Steroid and Immunosuppressive Drug Resistant Lupus nephritis by Intravenous Prostaglandin E1Therapy. Nephron. 1990;55:258–64. doi: 10.1159/000185972
  352. Jain H, Mittal A, Didel S, et al. Use of prostaglandin and cyclophosphamide for pediatric lupus with digital gangrene: Back to safety before hitting the axe! Lupus. 2023;32:1572–8. doi: 10.1177/09612033231208850
  353. https://pro.uptodatefree.ir/Show/13353. [Электронный ресурс] (дата обращения: 13.08.2024).
  354. Lamprecht P, Schnabel A, Gross WL. Efficacy of alprostadil and iloprost in digital necrosis due to secondary Raynaud’s phenomenon. Br J Rheumatol. 1998;37(6):703-704. [PubMed 9667634].
  355. Rodriguez MM, Wagner-Weiner L. Intravenous Immunoglobulin in Pediatric Rheumatology: When to Use It and What Is the Evidence. Pediatr Ann. 2017;46. doi: 10.3928/19382359-20161214-01
  356. Bertsias GK, Ioannidis JPA, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69:2074–82. doi: 10.1136/ard.2010.130476
  357. Koç R, Sönmez HE, Çakan M, et al. Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years’ experience of a tertiary pediatric rheumatology center. Rheumatol Int. 2020;40:771–6. doi: 10.1007/s00296-019-04498-z
  358. Watanabe Y, Yamaguchi Y. Drug allergy and autoimmune diseases. Allergol Int. 2022;71:179–84. doi: 10.1016/j.alit.2022.02.001
  359. Felix MMR, Kuschnir FC, Boechat JL, et al. Recent findings on drug hypersensitivity in children. Front Allergy. 2024;5:1330517. doi: 10.3389/falgy.2024.1330517
  360. Park JS, Suh DI. Drug Allergy in Children: What Should We Know? Clin Exp Pediatr. 2020;63:203–10. doi: 10.3345/kjp.2019.00675
  361. Yazicioglu M. Approach to drug allergies in the childhood. Türk Pediatri Arş. 2014;49:99–103. doi: 10.5152/tpa.2014.1944
  362. Paul F, Cartron G. Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Rev Clin Immunol. 2019;15:383–9. doi: 10.1080/1744666X.2019.1562905
  363. Sulieman SE, Metjian TA, Zaoutis TE, et al. Pneumocystis Pneumonia: Epidemiology and Options for Prophylaxis in Non-HIV Immunocompromised Pediatric Patients. Curr Fungal Infect Rep. 2014;8:45–55. doi: 10.1007/s12281-014-0177-y
  364. Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100:S1–276. doi: 10.1016/j.kint.2021.05.021
  365. Alexeeva EI, Denisova RV, Valieva SI, et al. Efficacy and safety of rituximab in children with systemic lupus erythematosus: results of a retrospective study of the case series. Curr Pediatr. 2016;15:497–504. doi: 10.15690/vsp.v15i5.1624
  366. Кокина М.Ю., Фомина Д.С., Лебедкина М.C., Мутовина З.Ю., Жолобова Е.С., Курбанова С.Х., Наргизян А.К., Фетисова А.Н., Анджель А.Е., Дворяковская Т.М., Шилькрот И.Ю., Алексеева Е.И. Эффективность и безопасность применения двухкомпонентного препарата моноклональных антител к SARS-CoV-2 (тиксагевимаб + цилгавимаб) для доконтактной профилактики новой коронавирусной инфекции у иммунокомпрометированных пациентов детского возраста с ревматическими заболеваниями. Предварительные результаты первого в Российской Федерации проспективного наблюдательного когортного исследования. Вопросы практической педиатрии. 2023; 18(1): 16–26
  367. Kostopoulou M, Fanouriakis A, Cheema K, et al. Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations. RMD Open. 2020;6:e001263. doi: 10.1136/rmdopen-2020-001263
  368. Pons-Estel BA, Bonfa E, Soriano ER, et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus )–Pan-American League of Associations of Rheumatology (PANLAR). Ann Rheum Dis. 2018;77:1549–57. doi: 10.1136/annrheumdis-2018-213512
  369. Tunnicliffe DJ, Palmer SC, Henderson L, et al. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev. 2018;2018. doi: 10.1002/14651858.CD002922.pub4
  370. Chen W, Tang X, Liu Q, et al. Short-term Outcomes of Induction Therapy With Tacrolimus Versus Cyclophosphamide for Active Lupus Nephritis: A Multicenter Randomized Clinical Trial. Am J Kidney Dis. 2011;57:235–44. doi: 10.1053/j.ajkd.2010.08.036
  371. Chen X, Wang D, Li Z. Analysis of time course and dose effect of tacrolimus on proteinuria in lupus nephritis patients. J Clin Pharm Ther. 2021;46:106–13. doi: 10.1111/jcpt.13260
  372. Lee YH, Song GG. Efficacy and safety of tacrolimus versus mycophenolate mofetil as induction treatment and low-dose tacrolimus as treatment for lupus nephritis: a meta-analysis. Z Für Rheumatol. 2023;82:754–62. doi: 10.1007/s00393-022-01313-2
  373. Zheng X, Ouyang X, Cheng C, et al. Efficacy and safety of multi-target therapy in children with lupus nephritis. Pediatr Res. 2023;94:2040–6. doi: 10.1038/s41390-023-02747-3
  374. Chowdhary VR. Broad Concepts in Management of Systemic Lupus Erythematosus. Mayo Clin Proc. 2017;92:744–61. doi: 10.1016/j.mayocp.2017.02.007
  375. Liu Z, Zhang H, Liu Z, et al. Multitarget Therapy for Induction Treatment of Lupus Nephritis: A Randomized Trial. Ann Intern Med. 2015;162:18–26. doi: 10.7326/M14-1030
  376. Touma Z, Urowitz MB, Ibañez D, et al. Time to Recovery from Proteinuria in Patients with Lupus Nephritis Receiving Standard Treatment. J Rheumatol. 2014;41:688–97. doi: 10.3899/jrheum.130005
  377. Chan EY, Lai FF, Ma AL, et al. Managing Lupus Nephritis in Children and Adolescents. Pediatr Drugs. 2024;26:145–61. doi: 10.1007/s40272-023-00609-3
  378. Stohl W, Kwok A. Belimumab for the treatment of pediatric patients with lupus nephritis. Expert Opin Biol Ther. 2023;23:243–51. doi: 10.1080/14712598.2023.2178297
  379. Hu Y, Yuan J, Wang B, et al. Efficacy of belimumab for severe childhood-onset systemic lupus erythematosus with diffuse proliferative glomerulonephritis: A case report. Medicine (Baltimore). 2023;102:e34800. doi: 10.1097/MD.0000000000034800
  380. Li H, Chen C, Yang H, et al. Efficacy and safety of belimumab combined with the standard regimen in treating children with lupus nephritis. Eur J Pediatr. Published Online First: 28 June 2024. doi: 10.1007/s00431-024-05662-9
  381. Aleksandrov AA, Kisliak OA, Leontyeva IV. Clinical guidelines on arterial hypertension diagnosis, treatment and prevention in children and adolescents. Syst Hypertens. 2020;17:7–35. doi: 10.26442/2075082X.2020.2.200126
  382. Madison JA, Zuo Y, Knight JS. Pediatric antiphospholipid syndrome. Eur J Rheumatol. 2020;7:S3–12. doi: 10.5152/eurjrheum.2019.19160
  383. Groot N, De Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Ann Rheum Dis. 2017;76:1637–41. doi: 10.1136/annrheumdis-2016-211001
  384. Rup AR, Dash AK, Behera JR, et al. Antiphospholipid Antibody Syndrome in Childhood Systemic Lupus Erythematous With a Unique Presentation: A Case Report. Cureus. Published Online First: 24 July 2022. doi: 10.7759/cureus.27205
  385. Li G, Li Y, Zeng Q, et al. Lupus podocytopathy and antiphospholipid syndrome in a child with SLE: A case report and literature review. Front Pediatr. 2022;10:950576. doi: 10.3389/fped.2022.950576
  386. Dima A, Jurcut C, Chasset F, et al. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis. 2022;14:1759720X211073001. doi: 10.1177/1759720X211073001
  387. Shin J, Kim KN. Catastrophic Antiphospholipid Syndrome Associated with Systemic Lupus Erythematosus Successfully Treated with Rituximab: A Case Report. J Rheum Dis. 2019;26:74. doi: 10.4078/jrd.2019.26.1.74
  388. Gallagher KL, Patel P, Beresford MW, et al. What Have We Learnt About the Treatment of Juvenile-Onset Systemic Lupus Erythematous Since Development of the SHARE Recommendations 2012? Front Pediatr. 2022;10:884634. doi: 10.3389/fped.2022.884634
  389. Shakoory B, Geerlinks A, Wilejto M, et al. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Ann Rheum Dis. 2023;82:1271–85. doi: 10.1136/ard-2023-224123
  390. Henter J-I. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100:2367–73. doi: 10.1182/blood-2002-01-0172
  391. Bagri NK, Gupta L, Sen ES, et al. Macrophage Activation Syndrome in Children: Diagnosis and Management. Indian Pediatr. 2021;58:1155–61. doi: 10.1007/s13312-021-2399-8
  392. Stephan JL. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology. 2001;40:1285–92. doi: 10.1093/rheumatology/40.11.1285
  393. I.A.Kriulin IAK, Kriulin IA, National Medical Research Center for Children’s Health, Moscow, Russian Federation, et al. Hemophagocytic lymphohistiocytosis: mechanisms of development, clinical manifestations, and treatments. Vopr Prakt Pediatr. 2021;16:94–102. doi: 10.20953/1817-7646-2021-6-94-102
  394. Bennett TD, Fluchel M, Hersh AO, et al. Macrophage activation syndrome in children with systemic lupus erythematosus and children with juvenile idiopathic arthritis. Arthritis Rheum. 2012;64:4135–42. doi: 10.1002/art.34661
  395. Lee J, Bae KS, Rhim JW, et al. Macrophage Activation Syndrome in Children: Update on Diagnosis and Treatment. Children. 2024;11:755. doi: 10.3390/children11070755
  396. Zhang H, Yang S-W, Fu Y-C, et al. Cytokine storm and targeted therapy in hemophagocytic lymphohistiocytosis. Immunol Res. 2022;70:566–77. doi: 10.1007/s12026-022-09285-w
  397. Криулин И.А., Алексеева Е.И., Шилькрот И.Ю., Дворяковская Т.М. Лечение вторичного гемофагоцитарного синдрома у пациентов с системным ювенильным идиопатическим артритом. Результаты когортного ретроспективного исследования. Вопросы практической педиатрии. 2022; 17(5): 7–19. DOI: 10.20953/1817-7646-2022-5-7-19.
  398. Pelewicz K, Miśkiewicz P. Glucocorticoid Withdrawal—An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice. Diagnostics. 2021;11:728. doi: 10.3390/diagnostics11040728
  399. Alves C, Robazzi TCV, Mendonça M. Withdrawal from glucocorticosteroid therapy: clinical practice recommendations. J Pediatr (Rio J). 2008;84:192–202. doi: 10.2223/JPED.1773
  400. Mouy R, Stephan J-L, Pillet P, et al. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: Report of five cases. J Pediatr. 1996;129:750–4. doi: 10.1016/S0022-3476(96)70160-9
  401. Georgiadou S, Gatselis NK, Stefos A, et al. Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and γ-immunoglobulin infusions. World J Clin Cases. 2019;7:3394–406. doi: 10.12998/wjcc.v7.i21.3394
  402. Sen E. S., Clarke S. L. N., Ramanan A. V. Macrophage activation syndrome //The Indian Journal of Pediatrics. – 2016. – Т. 83. – №. 3. – С. 248-253.
  403. Rao S, Abzug MJ, Carosone-Link P, et al. Intravenous Acyclovir and Renal Dysfunction in Children: A Matched Case Control Study. J Pediatr. 2015;166:1462-1468.e4. doi: 10.1016/j.jpeds.2015.01.023
  404. Kimberlin DW. Acyclovir Dosing in the Neonatal Period and Beyond. J Pediatr Infect Dis Soc. 2013;2:179–82. doi: 10.1093/jpids/pis138
  405. Clemente D, Cuadros EN, Lovillo MC, et al. Position statement on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies, part 3: precautions in situations of surgery, fever, and opportunistic infections. Eur J Pediatr. 2023;183:915–27. doi: 10.1007/s00431-023-05295-4
  406. Balfour HH, McMonigal KA, Bean B. Acyclovir therapy of varicella-zoster virus infections in immunocompromised patients. J Antimicrob Chemother. 1983;12:169–79. doi: 10.1093/jac/12.suppl_B.169
  407. Whitley RJ. Herpes simplex virus in children. Curr Treat Options Neurol. 2002;4:231–7. doi: 10.1007/s11940-002-0040-2
  408. Antiviral Drugs in Children and Adolescents. Pediatr Infect Dis. 2020;1:123–8. doi: 10.5005/jp-journals-10081-1221
  409. Adler SP, Marshall B. Cytomegalovirus Infections. ;11.
  410. Lin X, Wan Y, Liu Y. Efficacy of ganciclovir in the treatment of cytomegalovirus (CMV) infection in infants and its effect on inflammatory reaction and immune function. Am J Transl Res. 2023;15:6514–23.
  411. Shim GH. Treatment of congenital cytomegalovirus infection. Clin Exp Pediatr. 2023;66:384–94. doi: 10.3345/cep.2022.01032
  412. Zhang S, Zhu Y, Jin Y, et al. Difference between Acyclovir and Ganciclovir in the Treatment of Children with Epstein–Barr Virus-Associated Infectious Mononucleosis. Evid Based Complement Alternat Med. 2021;2021:1–6. doi: 10.1155/2021/8996934
  413. Pereira JF, Azevedo ALS, Pessoa-Filho M, et al. Research priorities for next-generation breeding of tropical forages in Brazil. Crop Breed Appl Biotechnol. 2018;18:314–9. doi: 10.1590/1984-70332018v18n3n46
  414. Awasthi S, Upreti S. Macrophage activation syndrome in a patient with systemic lupus erythematosus (SLE) and dual viremia. J Community Hosp Intern Med Perspect. 2020;10:470–4. doi: 10.1080/20009666.2020.1787811
  415. Peuchmaur M, Voisin J, Vaillant M, et al. Epstein-Barr Virus Encephalitis: A Review of Case Reports from the Last 25 Years. Microorganisms. 2023;11:2825. doi: 10.3390/microorganisms11122825
  416. Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol. 2013;162:376–82. doi: 10.1111/bjh.12386
  417. Law C, Raffini L. A Guide to the Use of Anticoagulant Drugs in Children. Pediatr Drugs. 2015;17:105–14. doi: 10.1007/s40272-015-0120-x
  418. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736–45. doi: 10.1136/annrheumdis-2019-215089
  419. Valade S, Mariotte E, Azoulay E. Coagulation Disorders in Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome. Crit Care Clin. 2020;36:415–26. doi: 10.1016/j.ccc.2019.12.004
  420. Carcillo JA, Shakoory B, Castillo L. Secondary Hemophagocytic Lymphohistiocytosis, Macrophage Activation Syndrome, and Hyperferritinemic Sepsis-Induced Multiple-Organ Dysfunction Syndrome in the Pediatric ICU. In: Mastropietro CW, Valentine KM, eds. Pediatric Critical Care. Cham: Springer International Publishing 2019:245–55.
  421. Алексеева Е., Валиева С., Бзарова Т., Семикина Е., Исаева К., Лисицин А., Денисова Р., Чистякова Е., Слепцова Т., Митенко Е. Эффективность и безопасность отечественного рекомбинантного человеческого гранулоцитарного колониестимулирующего фактора при нейтропениях, развивающихся на фоне анти-в клеточной и иммуносупрессивной терапии у больных ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2010;9(4):94-100.
  422. Yilmaz D., Ritchey A. K. Severe neutropenia in children: a single institutional experience //Journal of Pediatric Hematology/Oncology. – 2007. – Т. 29. – №. 8. – С. 513-518.
  423. Torres Jiménez A, Solís Vallejo E, Zeferino Cruz M, et al. Macrophage Activation Syndrome as the Initial Manifestation of Severe Juvenile Onset Systemic Lupus Erythematosus. Favorable Response to Cyclophosphamide. Reumatol Clínica Engl Ed. 2014;10:331–5. doi: 10.1016/j.reumae.2013.12.009
  424. Segel, G. B., & Halterman, J. S. (2008). Neutropenia in pediatric practice. Pediatrics in review, 29(1), 12.
  425. Demirkol D, Yildizdas D, Bayrakci B, et al. Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment? Crit Care. 2012;16:R52. doi: 10.1186/cc11256
  426. El-Nawawy A, El-Kinany H, Hamdy El-Sayed M, et al. Intravenous Polyclonal Immunoglobulin Administration to Sepsis Syndrome Patients: A Prospective Study in a Pediatric Intensive Care Unit. J Trop Pediatr. 2005;51:271–8. doi: 10.1093/tropej/fmi011
  427. Vassilopoulos A, McCormick W, Lakhani A. Update in Hyperferritinemic Syndromes: Recognition and Management - A Scoping Review. J Brown Hosp Med. 2022;1. doi: 10.56305/001c.37667
  428. Papa R, Natoli V, Caorsi R, et al. Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases. Pediatr Rheumatol. 2020;18:56. doi: 10.1186/s12969-020-00450-9
  429. Bhat CS, Shetty R, Ramesh D, et al. Anakinra in Refractory Multisystem Inflammatory Syndrome in Children (MIS-C). Indian Pediatr. 2021;58:994–6. doi: 10.1007/s13312-021-2340-1
  430. Kostik MM, Isupova EA, Belozerov K, et al. Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis. Front Pediatr. 2022;10:894846. doi: 10.3389/fped.2022.894846
  431. Phadke O, Rouster-Stevens K, Giannopoulos H, et al. Intravenous administration of anakinra in children with macrophage activation syndrome. Pediatr Rheumatol. 2021;19:98. doi: 10.1186/s12969-021-00585-3
  432. Eloseily EM, Weiser P, Crayne CB, et al. Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis. Arthritis Rheumatol. 2020;72:326–34. doi: 10.1002/art.41103
  433. Pal P, Bathia J, Giri PP, et al. Macrophage activation syndrome in pediatrics: 10 years data from an Indian center. Int J Rheum Dis. 2020;23:1412–6. doi: 10.1111/1756-185X.13915
  434. Методические рекомендации особенности клинических проявлений и лечения заболевания, вызванного новой коронавирусной инфекцией (covid-19) у детей. Версия 2. (утв. Минздравом России). URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/050/914/original/03062020_дети_COVID-19_v2.pdf.
  435. Wei A, Ma H, Li Z, et al. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children. Int J Hematol. 2020;112:568–76. doi: 10.1007/s12185-020-02936-4
  436. Kostik MM, Raupov RK, Suspitsin EN, et al. The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience. Front Pediatr. 2022;10:820586. doi: 10.3389/fped.2022.820586
  437. Pin A, Tesser A, Pastore S, et al. Biological and Clinical Changes in a Pediatric Series Treated with Off-Label JAK Inhibitors. Int J Mol Sci. 2020;21:7767. doi: 10.3390/ijms21207767
  438. Gómez Conde Santa Yarelis, Carrión Mendoza Reynaldo, del Toro Ravelo Laydenis María, Chia Proenza Daniel. Síndrome de activación de macrofágica como complicación de la artritis idiopática juvenil sistémica. Rev Cuba Reumatol  [Internet]. 2021  Ago [citado  2022  Ago  02] ;  23( 2 ): e209. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1817-59962021000200011&lng=es.  Epub 01-Ago-2021.
  439. Calvo-Alén J, Silva-Fernández L, Úcar-Angulo E, et al. Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en el lupus eritematoso sistémico. Reumatol Clínica. 2013;9:281–96. doi: 10.1016/j.reuma.2013.04.001
  440. Henter J-I, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31. doi: 10.1002/pbc.21039
  441. Неверов В. А., Камоско М. М., Басков В. Е. Эндопротезирование тазобедренного сустава у детей и подростков. //Вестник хирургии имени ИИ Грекова. – 2011. – Т. 170. – №. 6. – С. 107-112.
  442. Torchia ME, Klassen RA, Bianco AJ. Total Hip Arthroplasty with Cement in Patients Less Than Twenty Years Old. Long-Term Results*: J Bone Jt Surg. 1996;78:995–1003. doi: 10.2106/00004623-199607000-00003
  443. Yamamoto EA, Jørgensen TN. Relationships Between Vitamin D, Gut Microbiome, and Systemic Autoimmunity. Front Immunol. 2020;10:3141. doi: 10.3389/fimmu.2019.03141
  444. Rodriguez-Smith J, Brunner HI. Update on the treatment and outcome of systemic lupus erythematous in children. Curr Opin Rheumatol. 2019;31:464–70. doi: 10.1097/BOR.0000000000000621
  445. Novelli, V., & Holzel, H. (1999). Safety and tolerability of fluconazole in children. Antimicrobial agents and chemotherapy, 43(8), 1955-1960.
  446. Fernando MMA. How to monitor SLE in routine clinical practice. Ann Rheum Dis. 2005;64:524–7. doi: 10.1136/ard.2003.015248
  447. Garcia-Lloret M, McGhee S, Chatila TA. Immunoglobulin Replacement Therapy in Children. Immunol Allergy Clin North Am. 2008;28:833–49. doi: 10.1016/j.iac.2008.07.001
  448. Mulhearn B, Bruce IN. Indications for IVIG in rheumatic diseases. Rheumatology. 2015;54:383–91. doi: 10.1093/rheumatology/keu429
  449. Prasad AN, Chaudhary S. Intravenous immunoglobulin in pediatrics: A review. Med J Armed Forces India. 2014;70:277–80. doi: 10.1016/j.mjafi.2013.05.011
  450. Marco H, Smith RM, Jones RB, et al. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord. 2014;15:178. doi: 10.1186/1471-2474-15-178
  451. Barmettler S, Ong M-S, Farmer JR, et al. Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia. JAMA Netw Open. 2018;1:e184169. doi: 10.1001/jamanetworkopen.2018.4169
  452. Khojah AM, Miller ML, Klein-Gitelman MS, et al. Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases. Pediatr Rheumatol. 2019;17:61. doi: 10.1186/s12969-019-0365-y
  453. Gurbanov A, Gün E, Botan E, et al. Intravenous Immunoglobulin Use in Pediatric Intensive Care: A Single-Center Experience. 2023.
  454. Kostik MM, Kuchinskaya EM, Abduragimova FN, et al. Experience in Rituximab Administration in Children with Systemic Lupus Erythematosus: a Retrospective Study of the Case Series. Curr Pediatr. 2016;15:295–300. doi: 10.15690/vsp.v15i3.1567
  455. Mazo A, Duong MD, Sharma M, et al. Ambulatory Blood Pressure Patterns in Children, Adolescents, and Young Adults With Childhood-Onset Systemic Lupus Erythematosus and Normal Office Blood Pressure. JCR J Clin Rheumatol. 2022;28:328–31. doi: 10.1097/RHU.0000000000001884
  456. Canpolat N, Kasapcopur O, Caliskan S, et al. Ambulatory blood pressure and subclinical cardiovascular disease in patients with juvenile-onset systemic lupus erythematosus. Pediatr Nephrol. 2013;28:305–13. doi: 10.1007/s00467-012-2317-3
  457. Бельмер С.В., Корниенко Е.А., Волынец Г.В., Гурова М.М., Звягин А.А., Камалова А.А., Луппова Н.Е., Нижевич А.А., Новикова В.П., Печкуров Д.В., Приворотский В.Ф., Сатаев В.У., Тяжева А.А., Файзуллина Р.А., Хавкин А.И. Диагностика и лечение хеликобактерной инфекции у детей. Экспериментальная и клиническая гастроэнтерология. 2021;(9):119-127. https://doi.org/10.31146/1682-8658-ecg-193-9-119-127
  458. Kotilea K, Cadranel S, Salame A, et al. Efficacy and safety of bismuth‐based quadruple therapy for Helicobacter pylori eradication in children. Helicobacter. 2021;26:e12825. doi: 10.1111/hel.12825
  459. Pneumonia in Immunocompromised Patients: Overview, Causes of Pneumonia, HIV/AIDS. Published Online First: 26 June 2021.https://emedicine.medscape.com/article/807846-overview#a11.. (accessed 10 Aug 2021).
  460. Siberry GK, Abzug MJ, Nachman S, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children: Recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Pediatr Infect Dis J. 2013;32:i. doi: 10.1097/01.inf.0000437856.09540.11
  461. Douglas AP, Smibert OliviaC, Bajel A, et al. Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021. Intern Med J. 2021;51:143–76. doi: 10.1111/imj.15591
  462. What’s New Adult and Adolescent Opportunistic Infection. AIDSinfo. https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/392/whats-new (accessed 14 Apr 2020).
  463. Islam MdA, Khandker SS, Alam SS, et al. Vitamin D status in patients with systemic lupus erythematosus (SLE): A systematic review and meta-analysis. Autoimmun Rev. 2019;18:102392. doi: 10.1016/j.autrev.2019.102392
  464. Bachrach LK, Ward LM. Clinical Review: Bisphosphonate Use in Childhood Osteoporosis. J Clin Endocrinol Metab. 2009;94:400–9. doi: 10.1210/jc.2008-1531
  465. Kutilek S, Plasilova I, Langer J. Ibandronate in the treatment of pediatric osteoporosis. Bone Abstracts. Bioscientifica 2015.
  466. Денисова Р., Алексеева Е., Пинелис В., Баканов М., Валиева С., Бзарова Т., Исаева К., Морев С., Кузнецова Г. Эффективность и безопасность ибандроновой кислоты для внутривенного введения при тяжелом системном остеопорозе у больных ювенильным артритом. Вопросы современной педиатрии. 2011;10(6):83–88.
  467. Лисицин А., Алексеева Е., Пинелис В., Баканов М., Валиева С., Бзарова Т. Опыт применения ибандроновой кислоты у больных с тяжелым течением ревматических болезней и системным остеопорозом. вопросы современной педиатрии. 2010;9(1):116-121.
  468. Ladouceur A, Tessier-Cloutier B, Clarke AE, et al. Cancer and Systemic Lupus Erythematosus. Rheum Dis Clin N Am. 2020;46:533–50. doi: 10.1016/j.rdc.2020.05.005
  469. Trapani S, Grisolia F, Simonini G, et al. Incidence of occult cancer in children presenting with musculoskeletal symptoms: a 10-year survey in a pediatric rheumatology unit. Semin Arthritis Rheum. 2000;29:348–59. doi: 10.1053/sarh.2000.5752
  470. Zdrojewski Z. [Systemic lupus erythematosus and antiphospholipid syndrome - diagnostic and therapeutic problems]. Wiadomosci Lek Wars Pol 1960. 2018;71:40–6.
  471. Ahluwalia J, Singh S, Naseem S, et al. Antiphospholipid antibodies in children with systemic lupus erythematosus: a long-term clinical and laboratory follow-up status study from northwest India. Rheumatol Int. 2014;34:669–73. doi: 10.1007/s00296-013-2736-x
  472. Heijstek MW, Ott de Bruin LM, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70:1704–12. doi: 10.1136/ard.2011.150193
  473. Koç R, Sönmez HE, Çakan M, et al. Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years’ experience of a tertiary pediatric rheumatology center. Rheumatol Int. Published Online First: 21 December 2019. doi: 10.1007/s00296-019-04498-z
  474. Prasetya, Damar & Sumadiono, & Julia, Madarina. (2019). Risk Factors of Steroid-induced Hyperglycemia in Childhood Systemic Lupus Erythematosus.
  475. Whittle, Vanessa & Gane, J & Cheetham, T. (2017). G169(P) Management of steroid induced diabetes in children: A national perspective. Archives of Disease in Childhood. 102. A69.1-A69. 10.1136/archdischild-2017-313087.168.
  476. Groot N, De Graeff N, Marks SD, et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis. 2017;76:1965–73. doi: 10.1136/annrheumdis-2017-211898

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*